Generex Biotechnology (GNBTQ) 10-Q 22 Jun 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Apr. 30, 2020	Jun. 17, 2020
Document And Entity Information
Entity Registrant Name	GENEREX BIOTECHNOLOGY CORP
Entity Central Index Key	0001059784
Current Fiscal Year End Date	--07-31
Entity Filer Category	Non-accelerated Filer
Entity's Reporting Status Current	Yes
Entity Incorporation, State or Country Code	DE
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity File Number	0-25169
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Apr. 30, 2020
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2020
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding		79,936,996

UNAUDITED CONDENSED INTERIM CON

UNAUDITED CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS - USD ($)	Apr. 30, 2020	Jul. 31, 2019
Current assets
Cash and cash equivalents	$ 416,643	$ 298,485
Accounts receivable, net	142,000	36,311
Inventory, net	910,984	363,008
Other current assets	623,844	275,731
Total Current Assets	2,093,471	973,535
Property and equipment	244,822	499,993
Goodwill	38,901,126	38,297,573
Intangible assets	10,494,574	9,834,269
Operating lease right-of-use assets - net	138,711	0
Other assets, net	22,421	30,621
TOTAL ASSETS	51,895,125	49,635,991
Current liabilities
Accounts payable and accrued expenses	21,537,332	14,684,060
Notes payable, current	11,565,791	8,368,379
Payable to foundation for services	1,315,817	1,315,817
Interest payable to foundation	3,682,812	3,055,945
Loans from related parties	29,700	19,700
Operating lease liabilities - current	79,704	0
Deferred tax liability	1,502,122	1,502,122
Total Current Liabilities	39,713,278	28,946,023
Notes payable - noncurrent	499,473	0
Derivative liability	10,320,061	7,820,283
Common stock payable	186,972	1,123,188
Operating lease liabilities - net of current portion	60,309	0
Total Liabilities	50,780,093	37,889,494
Redeemable non-controlling interest (Note 11)	4,073,898	4,073,898
Stockholders' equity (defiency) (Note 10)
Common stock, $0.001 par value; authorized 750,000,000 shares;79,936,996 and 78,608,419 issued and outstanding at April 30, 2020 and July 31, 2019, respectively	79,937	78,608
Subscription receivable	(767,690)	0
Additional paid-in capital	427,623,151	408,550,211
Accumulated deficit	(440,389,785)	(418,727,875)
Accumulated other comprehensive income	792,233	797,216
Non-controlling interest	9,703,288	16,974,439
Total stockholders' equity (deficiency)	(2,958,866)	7,672,599
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY)	$ 51,895,125	$ 49,635,991

UNAUDITED CONDENSED INTERIM C_2

UNAUDITED CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Apr. 30, 2020	Jul. 31, 2019
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued	79,936,996	78,608,419
Common stock, shares outstanding	79,936,996	78,608,419

UNAUDITED CONDENSED INTERIM C_3

UNAUDITED CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2019
Income Statement [Abstract]
Revenue, net	$ 498,676	$ 1,092,926	$ 2,077,764	$ 6,254,339
Cost of Goods Sold	116,292	1,264,964	415,569	4,147,264
Gross profit (loss)	382,384	(172,038)	1,662,195	2,107,075
Operating expenses
Research and development	332,029	472,010	1,270,600	1,463,015
Bad debt expense	0	0	14,146	0
General and administrative	3,624,709	8,656,877	13,058,813	17,428,182
Total operating expenses	3,956,738	9,128,887	14,343,559	18,891,197
Operating Loss	(3,574,354)	(9,300,925)	(12,681,364)	(16,784,122)
Other Income (Expense):
Interest expense	(1,506,103)	(2,328,703)	(5,453,268)	(4,591,639)
Interest income	5	2,855	1,092	3,623
Changes in fair value of contingent purchase consideration	(119,630)	0	(119,630)	15,147,591
Change in fair value of derivative liability	(466,217)	417,330	(4,112,208)	560,055
Change in fair value of common stock payable	(96,183)	0	18,871	0
Impairment of long lived assets	0	0	0	(99,519)
Other income, net	1,665	56,135	(6,887)	8,699
Net loss	(5,760,817)	(11,153,308)	(22,353,394)	(5,755,312)
Net loss attributable to noncontrolling interests	(134,355)	(839,419)	(691,484)	(1,199,822)
Net loss available to common stockholders	$ (5,626,462)	$ (10,313,889)	$ (21,661,910)	$ (4,555,490)
Basic	$ (0.07)	$ (0.12)	$ (0.31)	$ (0.06)
Diluted	$ (0.07)	$ (0.12)	$ (0.31)	$ (0.06)
Basic	76,976,925	84,507,030	70,702,570	74,445,373
Diluted	76,976,925	84,507,030	70,702,570	74,445,373
Comprehensive loss
Net loss	$ (5,626,462)	$ (10,313,889)	$ (21,661,910)	$ (4,555,490)
Change in foreign currency translation adjustments	17,042	7,318	(4,983)	9,342
Comprehensive (Loss) Income Available to Common Stockholders	$ (5,609,420)	$ (10,306,571)	$ (21,666,893)	$ (4,546,148)

UNAUDITED CONDENSED INTERIM C_4

UNAUDITED CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY) - USD ($)	Preferred Stock	Common Stock	Common Stock Payable	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Sub Total	Noncontrolling Interest	Redeemable Non-controlling Interest	Total
Balance at Jul. 31, 2018	$ 4	$ 31,402	$ 2,168,951	$ 368,379,293	$ (409,386,468)	$ 798,422	$ (38,008,396)	$ (5,576,272)		$ (43,584,668)
Balance (in shares) at Jul. 31, 2018	79,590	31,402,169
Investment in subsidiary by noncontrolling interest								228,789		228,789
Conversion of preferred series H	$ (3)	$ 28,829		(28,826)
Conversion of preferred series H (in shares)	(63,000)	28,828,953
Conversion of preferred series I	$ (1)	$ 7,584		(7,583)
Conversion of preferred series I (in shares)	(16,590)	7,583,560
Elimination of non-controlling interest				(6,951,015)			(6,951,015)			(6,951,015)
Issuance of common stock payable		8,495	(1,967,657)	1,959,162
Issuance of stock options				1,530,312			1,530,312			1,530,312
Extinguishment of debt		46		14,056,067			14,056,113			14,056,113
Issuance of warrants				9,032,435			9,032,435			9,032,435
Antigen dividend				(1,070,456)			(1,070,456)	1,070,456
Conversion of debt to equity - Veneto				13,929,129			13,929,129			13,929,129
Conversion of debt to equity - Veneto (in shares)
Acquisition of NCI of Regentys								9,870,762		9,870,762
Acquisition of NCI of Olaregen								11,999,559		11,999,559
Acquisition of NCI of HDS								5,565,285		5,565,285
Reclassification of equity to liability			(201,294)				(201,294)			(201,294)
Redeemable non-controlling interest									4,073,898	4,073,898
Currency translation adjustment						9,342	9,342			9,342
Settlement of subsidiary's liability with stock										0
Net Income (Loss)					(4,555,490)		(4,555,490)	(1,199,822)		(5,755,312)
Balance at Apr. 30, 2019		$ 76,356		400,828,518	(413,941,958)	807,764	(12,229,320)	21,958,757	4,073,898	13,803,335
Balance (in shares) at Apr. 30, 2019		76,356,640
Balance at Jan. 31, 2019		$ 76,356	201,294	387,364,374	(403,628,069)	800,446	(15,185,599)	21,683,698	4,073,898	10,571,997
Balance (in shares) at Jan. 31, 2019		76,356,640
Investment in subsidiary by noncontrolling interest								44,022		44,022
Issuance of stock options				605,471			605,471			605,471
Extinguishment of debt				13,929,129			13,929,129			13,929,129
Antigen dividend				(1,070,456)			(1,070,456)	1,070,456
Reclassification of equity to liability			(201,294)				(201,294)			(201,294)
Currency translation adjustment						7,318	7,318			7,318
Net Income (Loss)					(10,313,889)		(10,313,889)	(839,419)		(11,153,308)
Balance at Apr. 30, 2019		$ 76,356		400,828,518	(413,941,958)	807,764	(12,229,320)	21,958,757	$ 4,073,898	13,803,335
Balance (in shares) at Apr. 30, 2019		76,356,640
Balance at Jul. 31, 2019		$ 78,608		408,550,211	(418,727,875)	797,216	(9,301,840)	16,974,439		7,672,599
Balance (in shares) at Jul. 31, 2019		78,608,419
Stock compensation expense				1,630,111			1,630,111			1,630,111
Shares issued for services		$ 670		292,930			293,600			293,600
Shares issued for services (in shares)		669,803
Shares issued for deferred offering		$ 1,720	(767,690)	765,970
Shares issued for deferred offering (in shares)		1,719,901
Issuance of common stock for acquisitions		$ 960		1,150,992			1,151,952			1,151,952
Issuance of common stock for acquisitions (in shares)		960,000
Reduction of derivative liabilities				3,041,502			3,041,502			3,041,502
Cancellation of shares		$ (20,376)		20,376
Cancellation of shares (in shares)		(20,375,900)
Purchase of shares in subsidiary		$ 7,856		6,571,811			6,579,667	(6,579,667)
Purchase of shares in subsidiary (in shares)		7,855,912
Shares issued as debt issuance cost		$ 343		150,887			151,230			151,230
Shares issued as debt issuance cost (in shares)		343,000
Issuance of common stock payable		$ 436		935,959			936,395			936,395
Issuance of common stock payable (in shares)		436,121
Conversion of debt to equity		$ 9,720		4,480,190			4,489,910			4,489,910
Conversion of debt to equity (in shares)		9,719,740
Currency translation adjustment						(4,983)	(4,983)			(4,983)
Settlement of subsidiary's liability with stock				32,212			32,212			32,212
Net Income (Loss)					(21,661,910)		(21,661,910)	(691,484)		(22,353,394)
Balance at Apr. 30, 2020		$ 79,937	(767,690)	427,623,151	(440,389,785)	792,233	(12,662,155)	9,703,288		(2,958,866)
Balance (in shares) at Apr. 30, 2020		79,936,996
Balance at Jan. 31, 2020		$ 69,127	(767,690)	420,206,242	(434,763,323)	775,191	(14,480,453)	14,429,920		(50,533)
Balance (in shares) at Jan. 31, 2020		69,129,001
Stock compensation expense				393,414			393,414			393,414
Shares issued for services		$ 110		49,890			50,000			50,000
Shares issued for services (in shares)		109,803
Reduction of derivative liabilities				765,424			765,424			765,424
Purchase of shares in subsidiary		$ 5,950		4,586,327			4,592,277	(4,592,277)
Purchase of shares in subsidiary (in shares)		5,950,000
Shares issued as debt issuance cost		$ 35		9,205			9,240			9,240
Shares issued as debt issuance cost (in shares)		35,000
Conversion of debt to equity		$ 4,715		1,580,437			1,585,152			1,585,152
Conversion of debt to equity (in shares)		4,713,192
Currency translation adjustment						17,042	17,042			17,042
Settlement of subsidiary's liability with stock				32,212			32,212			32,212
Net Income (Loss)					(5,626,462)		(5,626,462)	(134,355)		(5,760,817)
Balance at Apr. 30, 2020		$ 79,937	$ (767,690)	$ 427,623,151	$ (440,389,785)	$ 792,233	$ (12,662,155)	$ 9,703,288		$ (2,958,866)
Balance (in shares) at Apr. 30, 2020		79,936,996

UNAUDITED CONDENSED INTERIM C_5

UNAUDITED CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net (Loss) Income	$ (22,353,394)	$ (5,755,312)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	609,007	550,285
Amortization of operating lease right-of-use assets	71,987	0
Stock compensation expense	1,630,111	1,530,312
Shares issued for services	293,600	0
Changes in fair value of contingent purchase consideration	0	(15,147,591)
Loss on disposal of fixed assets	189,366	0
Increase in notes payable due to default	94,214	0
Amortization of debt discount	3,795,606	1,128,613
Non-cash interest expense from issuance on debt (derivative)	0	959,974
Change in fair value of derivative liabilities - convertible notes	(642,221)	(1,034,180)
Change in fair value of derivative liabilities - convertible warrants	(9,913)	(95,986)
Change in fair value of derivative liabilities - downside protection	4,764,341	570,112
Change in fair value of common stock payable	(18,871)	0
Impairment of long-lived assets	0	99,519
Bad debt expense	10,981	0
Changes in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable	16,599	735,317
Inventory	(281,905)	1,239,411
Accounts payable and accrued expenses	6,061,988	6,583,739
Interest payable to foundation	626,867	524,303
Accrued interest on notes receivable	0	(38,401)
Loans from related parties	0	0
Operating lease liabilities	(70,685)	0
Other current assets	(286,096)	106,160
Other assets	11,383	(21,597)
Other current liabilities	0	4,702
Other liabilities	0	2,233
Net cash used in operating activities	(5,487,035)	(8,058,387)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(4,616)	(285,670)
Purchase of intangible assets	0	(26,487)
Disposal of property and equipment	0	252,012
Disposal of intangible assets	0	62,091
Cash received in acquisition of a business, net of cash paid	49,305	2,280,425
Net cash provided by investing activities	44,689	2,282,371
CASH FLOWS FROM FINANCING ACTIVITIES
Loan proceeds from related party	10,000	(3,305)
Payment of notes payable	(935,731)	(27,248)
Proceeds from note payable	6,381,448	5,929,910
Proceeds from issuance of common stock	109,770	0
Investment in subsidiary by noncontrolling interest	0	228,789
Net cash provided by financing activities	5,565,487	6,128,146
Effects of currency translation on cash and cash equivalents	(4,983)	9,342
Net increase in cash and cash equivalents	118,158	361,472
Cash and cash equivalents, beginning of period	298,485	1,046,365
Cash and cash equivalents, end of period	416,643	1,407,837
Supplemental Disclosure of Cash Flow Information
Cash paid for interest	25,000	0
Cash paid for taxes	0	0
Supplemental Disclosure of Non-Cash Investing and Financing Activities
Reduction of derivative liabilities	3,041,502	0
Discount on derivative liability upon issuance of debt	1,834,607	0
Issuance of common stock for conversion of debt	4,489,910	0
Set up of ROU	210,698	0
Issuance of shares-common stock payable	936,395	0
Subscription receivable	765,970	0
Shares issued as debt issuance cost	151,230	0
Issuance of debt for payment of prepaid expense	50,000	0
Settlement of subsidiary’s liability with stock	32,212	0
Conversion of HDS debt and issuance of call option	$ 0	$ 14,056,113

Organization of Business and Go

Organization of Business and Going Concern	9 Months Ended
	Apr. 30, 2020
Accounting Policies [Abstract]
Organization of Business and Going Concern	Note 1 – Organization of Business and Going Concern: Generex Biotechnology Corporation (“Generex”, “Company”, "we", "us" or "our"), was formed in the State of Delaware on September 4, 1997 and its year-end is July 31. It is engaged primarily in the research and development of drug delivery systems and the use of the Company’s proprietary technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator; and through the Company’s subsidiary, NuGenerex Immuno-Oncology (“NGIO”), formerly Antigen Express, Inc., or “Antigen”), has undertaken work on immunomedicines incorporating proprietary vaccine formulations. GNBT distributed a total of approximately 34 million shares of NGIO in two dividends to GNBT shareholders on February 19, 2019 and February 24, 2020. Additional NGIO shares were used as consideration in various acquisitions by GNBT. After all of these transactions GNBT still owns over 90% of the outstanding shares of NGIO requiring GNBT to continue to consolidate NGIO. On March 12, 2020, NGIO filed a Form 10 registration statement. This form 10 became effective on May 11, 2020 at which time NGIO became a reporting entity controlled by GNBT. As a result of these transactions, GNBT shall recognize the non-controlling interest in NGIO in its financial statements. On January 18, 2017, the Company closed an Acquisition Agreement pursuant to which the Company acquired a 51% interest in NuGenerex Diagnostics LLC “NGDx,” formerly known as Hema Diagnostic Systems, LLC, a Florida limited liability company established in December 2000 to market and distribute rapid test devices including infectious diseases. Since 2002, NGDx has been developing an expanding line of rapid diagnostic tests (RDTs) including such diseases as Human Immunodeficiency Virus (HIV) – 1/2, tuberculosis, malaria, hepatitis, syphilis, typhoid and dengue as well as other infectious diseases. Subsequently, on December 1, 2018, the Company closed the acquisition of the remaining 49% interest in NGDx to become a wholly owned subsidiary of the Company. On October 3, 2018, the Company entered into an Asset Purchase Agreement with Veneto Holdings, L.L.C. (“Veneto”) to purchase certain assets of Veneto and its subsidiaries. The Agreement bifurcated the closing. On October 3, 2018 (the “First Closing”), the Company purchased substantially all the operating assets of Veneto including (a)system of dispensing pharmacies, (b) one central adjudicating pharmacy, (c) a wholesale pharmaceutical purchasing company, and (d) an in-network laboratory. On November 1, 2018, the Company consummated the acquisition of the Second Closing Assets, consisting primarily of Veneto’s management services organization business and two additional ancillary services. In March 2019, the Company changed its business model to no longer utilize their existing pharmacies. Going forward Veneto will conduct business exclusively through their management services organization (“MSO”) and by entering into more ancillary provider service agreements with third party pharmacies as an effort to reduce fixed costs and salaries. This was made practicable due to the decrease in overall script volume coupled with delays in the Company being able to receive operating licenses from various government agencies. On January 7, 2019, the Company closed two separate Acquisition Agreements pursuant to which the Company acquired a 51% interest in both Regentys Corporation (“Regentys”) and Olaregen Therapeutix Inc. (“Olaregen”). Regentys is a regenerative medicine company focused on developing novel treatments for patients with gastrointestinal (GI) disorders. Olaregen is a New York based regenerative medicine company that is preparing to launch its proprietary, patented, wound conforming gel matrix, Excellagen, an FDA 510K cleared wound healing product. In the first quarter of 2020 the Company acquired increased its ownership of Olaregen to 77%. In the third quarter of 2020 the Company acquired the remaining interest in Olaregen in exchange for its shares of common stock and became a wholly owned subsidiary of the Company. On August 1, 2019, the Company, through its wholly owned subsidiary NDS, closed on Asset Purchase Agreements (the “APAs”) for the purchase of substantially all the operating assets of MediSource Partners, LLC (“MediSource”) and Pantheon Medical - Foot & Ankle, LLC (“Pantheon”). MediSource contracts with vendors (including Pantheon) for nationwide distribution of implants and devices for spine, hips, knees, foot, ankle, hand, and wrist surgeries. Additional product lines include biologics (blood, bone, tissue, and stem cells), durable medical equipment, and soft goods. MediSource also supplies kits to process bone marrow aspirates and platelet rich plasma biologics at the time of surgery. Pantheon sells a physician friendly, “all-in-one,” integrated kit that includes plates, screws, and tools required for orthopedic surgeons and podiatrists conducting foot and ankle surgeries. Over the next three years, Pantheon expects to develop and submit several new product lines to the FDA, which will include cannulated surgical screws and surgical staples, as well as a proprietary Hammertoe System. Going Concern The accompanying unaudited condensed interim consolidated financial statements have been prepared in conformity with generally accepted in the United States of America (“U.S. GAAP”), which contemplate continuation of the Company as a going concern. The Company has experienced recurring net losses and negative cash flows from operations since inception and has an accumulated deficit of approximately $440.4 million and a working capital deficiency of approximately $37.6 million at April 30, 2020. The Company has funded its activities to date almost exclusively from debt and equity financings. The Company will continue to require substantial funds to implement its new investment acquisition plans. Management’s plans in order to meet its operating cash flow requirements include financing activities such as private placements of its common stock, preferred stock offerings, and issuances of debt and convertible debt instruments. Management is also actively pursuing financial and strategic alternatives, including strategic investments and divestitures, industry collaboration activities and strategic partners. The recent, widespread outbreak of a novel infectious disease called Coronavirus Disease 2019, or COVID-19, has created a dynamic and uncertain situation in the national economy. Regarding the Company, sales of Olaregen's Excellagen, Pantheon’s foot & ankle surgical kits, and the line of MediSource catalogue products have been significantly impacted by the COVID-19 pandemic. Surgeries and outpatient procedures were delayed and rescheduled, severely limiting sales of wound care and surgical products. Going forward, as the VA and other hospital systems re-open, the re-scheduled surgeries and procedures are expected to start up and create a backlog of cases, which should accelerate product sales to pre-COVID levels in due course. Because of the COVID-19 pandemic Generex and its subsidiaries are currently pursuing the development of a SARS-CoV-2 vaccine using the company's patented Ii-Key peptide vaccine technology. To this end, the Company applied for funding to BARDA in the U.S., Health Canada, and the Malaysian Ministry of Health as well as with CEPI, the international public/private consortium focused on the development of vaccines for the global market. To date, Generex has identified viral epitopes through computer vaccinology algorithms, and manufactured those peptide sequences with the Ii-Key moiety for testing in immunological screening program using convalescent blood samples from patients who have recovered from COVID-19. The immunological blood screening program is scheduled to begin shortly. Manufacturing partners have been identified for clinical and commercial supply. Completion of the ii-Key-SARS-CoV-2 peptide vaccine program is dependent on obtaining funding from government and/or private sources. The Company continues to closely monitor the latest information to make timely, informed business decisions and public disclosures regarding the potential impact of pandemic on its operations and financial condition. The scope of pandemic is unprecedented and its long-term impact on the Company’s operations and financial condition cannot be reasonably estimated at this time. There is always uncertainty and risk associated with the development of any vaccine, medical treatment or therapy, but the continued development depends upon the completing the trials under various collaboration agreements and associated potential commercialization of the product, FDA approval and/or licensing agreements. Any collaborator with whom we may enter into such collaboration agreements may not support fully our research and commercial interests since our program may compete for time, attention and resources with such collaborator's internal programs. Therefore, these collaborators may not commit sufficient resources to our program to move it forward effectively, or that the program will advance as rapidly as it might if we had retained complete control of all research, development, regulatory and commercialization decisions. During the pandemic COVID-19, it is anticipated that delays will occur, but the full impact of any slow down due to COVID-19 has not been determined. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the filing of this document. There are no assurances that such additional funding will be achieved and that the Company will succeed in its future operations. The unaudited condensed interim consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s inability to obtain required funding in the near future or its inability to obtain funding on favorable terms will have a material adverse effect on its operations and strategic development plan for future growth. If the Company cannot successfully raise additional capital and implement its strategic development plan, its liquidity, financial condition, and business prospects will be materially and adversely affected, and the Company may have to cease operations.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Apr. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies: Basis of Presentation The accompanying unaudited consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with accounting principles U.S. GAAP for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments, considered necessary for a fair presentation have been included. The Company’s fiscal year ends on July 31 of each calendar year. Each reference below to a fiscal year refers to the fiscal year ending in the calendar year indicated. Operating results for the three and nine months ended April 30, 2020 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2020. The balance sheet at April 30, 2020 does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Therefore, these condensed financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended July 31, 2019 as filed with the U.S. Securities and Exchange Commission (“SEC”). Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from those estimates. Business Combinations Acquisition cost is measured as the aggregate of the fair value at the date of acquisition of the assets given, equity instruments issued, or liabilities incurred or assumed. Acquisition related costs are expensed as incurred (except for those costs arising on the issue of equity instruments which are recognized directly in equity). Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured at fair value on the acquisition date. Goodwill is measured as the excess of the acquisition cost and the amount of any non-controlling interest, over the fair value of the identifiable net assets acquired. Revenue Recognition It is the Company’s policy that revenues from product sales is recognized in accordance with ASC 606 “Revenue Recognition.” Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that creates enforceable rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer. The amount of revenue recognized is the amount allocated to the satisfied performance obligation. Adoption of ASC 606 has not changed the timing and nature of the Company’s revenue recognition and there has been no material effect on the Company’s financial statements. Revenue from the pharmacy services is recognized when the prescription is dispensed (picked up by the patient or shipped to the patient using common carrier or delivered by the pharmacies own personnel). At the time of dispensing each pharmacy has a contract with the insurance payor (item (i)); the insurance payor has accepted the claim for reimbursement from the pharmacy (item ii) and informed the pharmacy how much will be paid for the prescription (item (iii)); the insurance payor is now legally obligated to make payment on the accepted claim within a given period proscribed by statute (item (iv)); and, the prescription has been taken from the pharmacy inventory, placed into an individually labeled container specific to the patient, and the patient is able to take possession of the prescription (item (v)). Shipment to or pick up by the patient is the first time that all criteria for revenue recognition have been met. Revenue from the laboratory services is recognized upon the completion of accessions (the requested laboratory test has been performed and the report has been issued to the requesting physician). After the test has been performed and reported, the insurance company and/or patient has an obligation to pay for medically necessary laboratory tests (items (i) and (ii)). Unlike the pharmacy services model, laboratory services are provided prior to insurance company approval; as a result, the seller’s price to buyer is not known until payment is provided (items (iii) and (iv). Based on historical collections, the Company estimates the expected revenues associated with similar tests and recognizes the revenue when testing results have been provided (v). Revenue from NGDx is recognized upon payment at the time the product(s) is released (shipment delivered using a common carrier), and the control is transferred which is simultaneous to when payment received and accepted. Revenue from product sales of Olaregen’s Excellagen® is recorded at the net sales price, or “transaction price,” which includes estimates of variable consideration that result from coupons, discounts, chargebacks and distributor fees, processing fees, as well as allowances for returns and government rebates. Revenue from product sales of Pantheon medical surgical kits used in surgical procedures is recorded all revenue is recognized at a point in time, generally when title of the product and control is transferred to the client which occurs upon the completion of surgical procedure when the product utilized and the medical facility provides a final list of products consumed. The Company constrains revenue by considering factors that could otherwise lead to a probable reversal of revenue. Where appropriate, the Company utilizes the expected value method to determine the appropriate amount for estimates of variable consideration based on factors such as the Company’s historical experience, contractual arrangement and specific known market events and trends. Collectability of revenue is reasonably assured based on historical evidence of collectability between the Company and its customers. Revenue from the provision of management services is recognized in accordance with the contractual terms of the relationship (item i); however, the current agreements in place typically specify that a percentage of the gross margin associated with the third-parties’ sales that the Company facilitates is to be remitted (iii), and as such, the revenue is considered earned upon completion of the third parties’ sales of such products (iv). Like pharmacy services described above, revenue is recognized when the prescription is dispensed (picked up by the patient or shipped to the patient using common carrier or delivered by the pharmacies own personnel) (v). Three months ended April 30, Nine months ended April 30, Revenue Source 2020 2019 2020 2019 Product sales $ 497,386 $ 37,300 $ 2,059,662 $ 37,300 Management services 1,290 80,471 18,168 283,319 Pharmacy sales — 1,020,616 — 5,615,153 Laboratory sales — (45,461 ) — 318,567 Total Revenue $ 498,676 $ 1,092,926 $ 2,077,830 $ 6,254,339 Provisions for estimated sales returns and uncollectible accounts are recorded in the period in which the related sales are recognized based on historical and anticipated rates. The Company determines whether it is the principal or agent for its retail pharmacy contract services on a contract by contract basis. In the majority of its contracts, the Company has determined it is the principal due to it: (i) being the primary obligor in the arrangement, (ii) having latitude in changing the product or performing part of the service, (iii) having discretion in supplier selection, (iv) having involvement in the determination of product or service specifications, and (v) having credit risk. The Company’s obligations under its client contracts for which revenues are reported using the gross method are separate and distinct from its obligations to the third-party pharmacies included in its retail pharmacy network contracts. Pursuant to these contracts, the Company is contractually required to pay the third-party pharmacies in its retail pharmacy network for products sold, regardless of whether the Company is paid by its clients. The Company’s responsibilities under its client contracts typically include validating eligibility and coverage levels, communicating the prescription price and the co-payments due to the third-party retail pharmacy, identifying possible adverse drug interactions for the pharmacist to address with the prescriber prior to dispensing, suggesting generic alternatives where clinically appropriate, and approving the prescription for dispensing. Although the Company does not have credit risk with respect to Retail Co-Payments or inventory risk related to retail network claims, management believes that all of the other applicable indicators of gross revenue reporting are present. For contracts under which the Company acts as an agent, revenue is recognized using the net method. Recently Issued Accounting Pronouncements In January 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception. Topic 480, Distinguishing Liabilities from Equity In February 2018, the FASB issued ASU 2018-02, Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement”, which adds disclosure requirements to Topic 820 for the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. This ASU is effective for interim and annual reporting periods beginning after December 15, 2019. The Company is evaluating the effect that ASU 2018-13 will have on consolidated financial statements.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Apr. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 3 - Commitments and Contingencies: Pending Litigation The Company is a defendant in one legal proceeding relating to alleged breach of contract and claims against certain of the Company’s original buccal delivery patents. The Company is also a defendant in two legal proceedings brought by a former executive officer and her affiliate. These legal proceedings have been reported in the Company’s prior periodic reports. No activity has occurred in these cases in several years, and the Company now considers them dormant. In December 2011, a vendor of the Company commenced an action against the Company and its subsidiary, Generex Pharmaceuticals, Inc., in the Ontario Superior Court of Justice claiming damages for unpaid invoices including interest in the amount of $429,000, in addition to costs and further interest. The Company responded to this statement of claim and also asserted a counterclaim in the proceeding for $200,000 arising from the vendor’s breach of contract and detinue, together with interest and costs. On November 16, 2012, the parties agreed to settle this action and the Company has agreed to pay the plaintiff $125,000, following the spinout of its subsidiary Antigen, from the proceeds of any public or private financing related to NGIO subsequent to such spinout. Each party agreed to execute mutual releases to the claim and counterclaim to be held in trust by each party’s counsel until payment of the settlement amount. Following payment to the plaintiff, the parties agree that a Consent Dismissal Order without costs will be filed with the court. If the Company fails to make the payment following completion of any post-spinout financing related to NGIO or any other subsidiaries, the Plaintiffs may take out a judgment in the amount of the claim plus interest of 3% per annum and costs fixed at $25,000. This has been accrued in the unaudited condensed interim consolidated financial statements. On August 22, 2017, Generex received a letter from counsel for Three Brothers Trading LLC, d/b/a Alternative Execution Group (“AEXG”), claiming breach of a Memorandum of Understanding (“MOU”) between Generex and AEXG. The MOU related to AEXG referring potential financing candidate to Generex. The letter from AEXG counsel claimed that Generex’s acceptance of $3,000,000 in financing from Pharma Trials, LLC, in March 2017, violated the provisions of the MOU prohibiting Generex from seeking other financing, with certain exceptions, for a period of 60 days after execution of the MOU. AEXG has demanded at least $210,000 in cash and 84,000 warrants for Generex stock convertible at $2.50 per share, for attorney’s fees and costs. AEXG filed a demand for arbitration and on September 25, 2018 an arbitration hearing was held with an arbitrator from the American Arbitration Association’s International Centre for Dispute Resolution. On December 3, 2018, an arbitrator awarded AEXG an aggregate of $315,695 in damages, costs and fees as well as warrants exercisable for 84,000 shares of Generex Common Stock at an exercise price of $2.50 per share. AEXG filed a petition to confirm the arbitrator’s award in the United States District Court for the Southern District of New York. The petition includes a demand of $3,300,360 as the value of the warrants. The arbitrator did not award the specific amount of $3.5 million, but only liquidated damages in the amount of $210,000 and the value of 84,000 warrants “as of today” (the date of the award) plus attorney’s fees, certain costs, prejudgment and post-judgment interest (which continues to run on a daily basis) and arbitration fees. Generex has responded that the value of the warrants on the date of the award is $0 or some figure far less than the value calculated by AEXG. The petition to confirm the arbitrator’s award and Generex’s opposition were remanded by the Court to the arbitrator and returned for clarification. The arbitrator stated that he was unable to add any clarification, as he did not take evidence on the issue of warrant valuation. AEXG filed a petition to confirm that part of the arbitrator’s award that awarded AEXG $210,000 in liquidated damages plus post award prejudgment interest. On April 24, 2020, legal fees in the amount of $93,304 plus costs of $12,393. The Court remanded part of the arbitrator’s award for a determination as to the economic value of 84,000 warrants with an exercise price of $2.50 per share. As of April 30, 2020, $285,613 has been accrued in relation to this matter. On June 28, 2018, the Company was named in respect of a claim by Burrard Pharmaceutical Enterprises Ltd. and Moa’yeri Kayhan for unspecified damages and other remedies issued by the Supreme Court of British Columbia. The claim is made in connection with one advanced against Burrard and Kayhan by Middle East Pharmaceutical Factory L.L.C., a foreign corporation, for fraudulent or negligent misrepresentation. Middle East alleges that it was misled by Burrard and Kayhan into believing that Burrard had rights to distribute Generex product in the Middle East. Burrard and Kayhan allege that they did have rights in that regard, which the Company denies. The matter remains at the pleadings stage and the Company is investigating the facts. On October 26, 2018, Generex entered into a Securities Purchase Agreement with an investor pursuant to which the Company agreed to sell and sold its Note due October 26, 2019 (“Note”) in the principal amount of $682,000. On January 25, 2019, Generex received a letter from the purchaser’s counsel stating that the Note was in default because Generex’s common stock was not listed on NASDAQ within 90 days after the issuance of the Note. The letter demanded repayment in full. On February 12, 2019, the Purchaser filed a Motion for Summary Judgment in lieu of complaint in the Supreme Court of New York, demanding the aggregate principal amount, default interest and costs. Purchaser’s motion for summary judgment was denied, and that that denial was upheld in the Appellate Division, Second Department. The Company is vigorously defending this matter. On March 21, 2019 Compass Bank filed suit against NuGenerex Distributions Solutions 2, L.L.C. in the District Court of Dallas County, Texas requesting damages of $3,413,000. In connection with the closing of the Veneto acquisition, Compass Bank had a lien on certain assets that were supposed to be transferred into the ownership of NuGenerex, a subsidiary of Generex. Those assets were never transferred due to regulatory impositions. Generex had listed Compass Bank as an intended third-party beneficiary to the transaction in relation to the assets liened and Veneto ceased payments upon the loan which the lien generated from. Compass bank filed suit against 6 parties involved in the transaction to collect on the loan, including NuGenerex. NuGenerex’s position is the contract was frustrated by the fact that the assets that were liened were never transferred by Veneto to NuGenerex, NuGenerex did not receive any benefit from the agreement, and thus NuGenerex is not responsible to Compass Bank for repayment of a loan on assets not transferred. Generex intends to implead Brooks Houghton for indemnification who was retained to perform due diligence on the transaction. In May 2019 Brooks Houghton threatened litigation by way of a FINRA Dispute Resolution, which was later filed against the Company. Brooks Houghton, who the managing representative is Mr. Centonfanti a prior board member, was under contract to perform due diligence on the Veneto transaction, as well as other unrelated items. The Veneto transaction closed three times, each time with a reduction in price due to material negative circumstances. Brook Houghton, who was under contract to perform due diligence, claims their fee should be paid on the initial closing price not the ultimate resolution of the matter. The company offered to compensate Brooks Houghton pursuant to agreement, 3% on the most recent closing price for Veneto for which Brooks Houghton may have performed some level of work on, payable in kind, and Brooks Houghton declined the offer. Brooks Houghton is claiming $450,000 for the first closing of Veneto, $714,000 for the second closing of Veneto, $882,353 for the Regentys acquisition, and $705,882 for Olaregen. The matter is set for a final hearing to commence on August 25, 2020. The Company has served its initial discovery in this matter. At this early stage, it is premature to express an opinion about possible outcome. As of April 30, 2020, the Company has accrued for the full $2,752,235 balance. On September 10, 2019, Generex and its subsidiaries, NuGenerex Distribution Solutions, LLC, and NuGenerex Distributions Solutions 2, LLC (jointly “NDS”) filed an arbitrary action against Veneto Holdings, LLC and certain affiliated entities holding shares of our common stock issued in connection with our acquisition of Veneto’s assets, alleging, among other things, that Veneto never transferred the ownership rights in at least one pharmacy to NDS. This pharmacy was a necessary element in the operation of other assets transferred by Veneto. The ownership rights in this pharmacy was a substantial portion of the consideration for shares issued to Veneto and its affiliates, and, as a result, Generex contends the shares issued to Veneto and its affiliates were never fully paid for. The arbitrator subsequently dismissed certain holders of the Company’s shares from the arbitration. The arbitration against Veneto is currently pending before the American Arbitration Association in Delaware. In a related action, our transfer agent has been sued for failure to process a transfer of the shares issued pursuant to the APA. This suit was brought in the United States District Court for the Eastern District of New York. Generex is not named in the suit, but our transfer agent has notified us of our obligation to indemnify them pursuant to our agreement with the transfer agent. On December 2, 2019, the Company was named as a respondent in an arbitration brought by KSKZ Management, LLC before the American Arbitration Association in Texas. The Claimant alleges that the Company breached a consulting agreement that purportedly obligated the Company to pay claimant a monthly consulting fee for three years. Kevin Kuykendall is the manager and a member of Claimant. Claimant is seeking approximately $3,450,000 in unpaid consulting fees allegedly due. The Company is vigorously defending itself and has filed counterclaims against Claimant. On February 18, 2020, the Company was named as a defendant in an action brought by Discover Growth Fund, LLC in the United States District Court for the District of Delaware. The plaintiff alleges that the Company breached a Purchase Agreement and Promissory Note and seeks $2,475,000 in damages. The plaintiff also filed a confession of judgment in support of its claim. On May 4, 2020, the District Court entered judgment against the Company for the balance of the note already accrued of $2,200,000. The Court will next consider the amount of attorneys fees that Discover is entitled to. Discover has communicated that they are entitled to $91,455 in attorneys fees and the Company has opposed this request. On May 6, 2020, the Company was named as a defendant in an action brought by Iliad Research and Trading LP (“Iliad”) in Salt Lake City, Utah. The plaintiff alleges that the Company breached a Securities Purchase Agreement and Convertible Promissory Note. The action seeks, among other things, a temporary restraining order preventing the Company from issuing new shares and an order compelling the Company to arbitrate the dispute with Iliad. On Friday, May 29, 2020, the Third District Court entered a ruling that Generex may not issue, transfer or otherwise dispose of any shares of stock without receiving court approval from the judge in the Utah Third District Court. The Company continues to contest the matter. With respect to all litigation, as additional information concerning the estimates used by the Company becomes known, the Company reassesses its position both with respect to accrued liabilities and other potential exposures. Commitments Intellectual Property In connection with the Company’s acquisition of Olaregen, intellectual property was acquired that had a valuation of $650,000 prior to being acquired and revalued. This initial $650,000 valuation represented the initial payment remitted by Olaregen in accordance with the $4 million signed commitment agreement entered into with Activation Therapeutics, Inc. The remaining $3.35 million balance is to be paid in quarterly installments equal to 10% of quarterly net sales generated by Activation Therapeutics assuming the Exellagen average selling price per unit exceeds $800. In the event that the average selling price per unit is less than $800 per unit, cost of goods sold shall be excluded from the computation of net sales. Acquisitions ALTuCELL On November 22, 2019, the Company entered into a Stock Purchase Agreement (“SPA”) for the purchase of 51% of the outstanding capital stock of GH Care, Inc. DBA ALTuCELL, Inc.(“ALTuCELL” ) Under the SPA, in exchange for the ALTuCELL Stock, Generex will issue to ALTuCELL 2,240,000 shares of Generex common stock with an attributed value of $4 million to be issued at the market price of the day at closing, but no less than $0.89 per share. The Company will also pay $2.5 million in cash of which $212,000 has already been paid. In addition to stock and cash at closing, Generex has agreed to pay up to an aggregate of $3,500,000 to ALTuCELL upon ALTuCELL’s attainment of certain milestones. On January 27, 2020, Generex and ALTuCELL executed an Amendment Agreement to the SPA (the “Amendment”). Under the Amendment, closing will occur within 30 days of the full execution of the Amendment, subject to the conditions to closing under the SPA. The parties agreed that Generex will pay the $2.5 million closing payment from certain specifically identified sources. If ALTuCELL chooses to cancel the transaction as a result of delays due to forces beyond the control of Generex, including government regulatory delays or extended reviews by regulators that delay approvals of corporate actions, or by natural disasters or other unforeseen events beyond the control of Generex, ALTuCELL, agrees to return all payments made by Generex. As of April 30, 2020, Generex has advanced $212,000 to ALTuCELL. As of the date of this filing, the acquisition did not close, however, both companies are negotiating the terms of the extension. Olaregen On November 24, 2019, the Company amended the Stock Purchase Agreement with Olaregen. The Company was obligated to pay in full $11,600,000 to Olaregen by November 30, 2019, in connection with the purchase of Olaregen capital stock. Effective November 24, 2019, the deadline was extended to January 31, 2020. The Company is negotiating the terms of a new extension and there has been no demand for payment at this time. Regentys On November 25, 2019, the Company amended the Stock Purchase Agreement with Regentys originally on January 7, 2019. Effective November 25, 2019, the remaining three payments of $2,039,001, $2,000,000, and $3,000,000 are all payable on or before December 30, 2019. The Company is negotiating the terms of a new extension and there has been no demand for payment at this time. Agreements On November 20, 2018, the Company entered into a clinical trial agreement with NSABP Foundation, Inc. (“NSABP”) under which NSABP will conduct clinical research using the Company’s AE37 peptide immunotherapeutic vaccine in combination with pembrolizumab (Ketruda®) for the treatment of metastatic triple negative breast cancer. The Company has agreed to pay NSABP an amount not to exceed $2,118,461 based on NAABP achieving various milestones. The Company recognized $340,000 as research and development related to the clinical trial agreement with NSABP as of April 30, 2020. On February 28, 2020, the Company entered into a Collaboration Agreement with Beijing Zhonghua Investment Fund Management Co., LTD and Sinotek-Advocates International Industry Development (Shenzhen) Co., Ltd. (an affiliate of China Technology Exchange) (the “Chinese Parties”), to develop a COVID-19 vaccine using the Ii-Key Peptide vaccine technology of NGIO. Under the Agreement, Generex will make the Ii-Key Peptide vaccine technology available to the Chinese Parties. The Chinese parties will provide facilities and personnel for the development of the COVID-19 vaccine under Generex/NGIO technical guidance. The development will include synthesis, analysis and human trials through Phase III, if warranted, in China. The Chinese parties will have exclusive rights to use and commercialize the COVID-19 technology and products in China. The Chinese Parties have agreed to set-aside $1,000,000 for Generex/NGIO expenses during development and human clinical trials. If development and testing are successful, the parties will enter into further collaboration and technology transfer agreements. In this event, the Chinese Parties have the following maximum commitment to NGIO: • A technology transfer fee of $5 million. • A 20% royalty. • Its accumulated cost for development of the technology. The Agreement provides Generex will receive a $2,000,000 breakup fee if China develops a cure for COVID-19. If Generex ceases its participation, Generex would be required to repay all amounts paid by the Chinese Parties on behalf of Generex. On March 3, 2020, the Company entered into a Master Services Agreement and Statement of Work Agreement with EpiVax, Inc. (“EpiVax”). The Agreement provides for EpiVax to use its proprietary epitope prediction software in the identification, development, and transfer of a potential vaccine for COVID-19 based upon Nugenerex Immuno-Oncology’s (“NGIO”) Ii-Key vaccine technology. NGIO is a majority owned subsidiary of Generex. Generex/NGIO will own the intellectual property generated by EpiVax’s work. The total fee for services is $325,000 of which $150,000 has been paid as of April 30, 2020. Payable to Foundation On February 1, 2007, the Company entered into a clinical study agreement with the Henry J. Jackson Foundation (the “Foundation” for the clinical research and development of AE37 for the treatment of breast cancer). The Company agreed to pay the foundation total compensation of $2,700,000 payable at various intervals over the term of the agreement. On September 9, 2013, the Company entered into a forbearance agreement (the “Forbearance Agreement”) with the Foundation and under which the Company n acknowledged that they were in arrears on its payment and interest obligations to the Foundation in the amount of $1,315,817. Pursuant to the Forbearance Agreement, the Company and the Foundation agreed that in exchange for deferring the overdue payments the Company would among other matters, pay the foundation (i) the final $200,000 upon completion of the study and acceptance of all study documents, (ii) a royalty of 5% of net third party sales and (iii) the original forbearance amount will continue to bear interest at 1.5% per month, compounded. The Foundation may terminate the Forbearance Agreement by providing the Company written notice should the Company, among other matters, fail to make payments due under the Forbearance Agreement. The foundation has not provided the study documents to the Company. As of April 30, 2020, and July 31, 2019, the Company’s payable to the foundation for services was $1,315,817. Interest payable to the Foundation was $3,682,812 and $3,055,945 as of April 30, 2020 and July 31, 2019, respectively. Interest accrued related to the payable to the foundation was $218,360 and $182,629, respectively for the three months ended April 30, 2020 and 2019; and $626,867 and $524,303, respectively, for the nine months ended April 30, 2020 and 2019.

Leases

Leases	9 Months Ended
	Apr. 30, 2020
Leases [Abstract]
Leases	Note 4 – Leases The Company has various operating lease agreements with terms up to 3 years, including leases of office space. Some leases include purchase, termination or extension options for one or more years. These options are included in the lease term when it is reasonably certain that the option will be exercised. The Company adopted ASC 842 effective August 1, 2019 using the cumulative-effect adjustment transition method, which applies the provisions of the standard at the effective date without adjusting the comparative periods presented. The Company adopted the following practical expedients and elected the following accounting policies related to this standard update: • The option to not reassess prior conclusions related to the identification, classification and accounting for initial direct costs for leases that commenced prior to August 1, 2019. • Short-term lease accounting policy election allowing lessees to not recognize right-of-use assets and liabilities for leases with a term of 12 months or less; and • The option to not separate lease and non-lease components for certain equipment lease asset categories such as freight car, vehicles and work equipment. • The package of practical expedients applied to all of its leases, including (i) not reassessing whether any expired or existing contracts are or contain leases, (ii) not reassessing the lease classification for any expired or existing leases, and (iii) not reassessing initial direct costs for any existing leases. The assets and liabilities from operating and finance leases are recognized at the commencement date based on the present value of remaining lease payments over the lease term using the Company’s incremental borrowing rates or implicit rates, when readily determinable. Short-term leases, which have an initial term of 12 months or less, are not recorded on the balance sheet. The Company’s operating leases do not provide an implicit rate that can readily be determined. Therefore, the Company uses a discount rate based on its incremental borrowing rate, which is determined using the average of borrowing rates explicitly stated in the Company’s convertible debt. The Company’s weighted-average remaining lease term relating to its operating leases is 1.47 years, with a weighted-average discount rate of 9.5%. The Company incurred lease expense for its operating leases of $82,715 for nine months ended April 30, 2020. The following table presents information about the amount and timing of liabilities arising from the Company’s operating leases as of April 30, 2020: Maturity of operating lease liabilities for the remainder of the current fiscal year and the following fiscal years: For the period May 1, 2020 to July 31, 2020 $ 30,109 2021 75,675 2022 38,139 2023 9,682 2024 — Thereafter $ — Total undiscounted operating lease payments 153,605 Less: Imputed interest 13,592 Present value of operating lease liabilities $ 140,013

Inventory

Inventory	9 Months Ended
	Apr. 30, 2020
Inventory Disclosure [Abstract]
Inventory	Note 5 – Inventory Inventory consists of the following components: April 30, July 31, 2020 2019 Raw materials $ 278,310 $ 77,782 Finished goods 632,674 285,226 Total Inventory $ 910,984 $ 363,008

Property and Equipment

Property and Equipment	9 Months Ended
	Apr. 30, 2020
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 6 – Property and Equipment Property and equipment, net consisted of the following: April 30, July 31, 2020 2019 Computers and technological assets $ 53,314 $ 163,168 Machinery and equipment 329,976 386,929 Furniture and fixtures 18,725 73,227 Leasehold Improvements 16,596 16,596 418,611 639,920 Less accumulated depreciation (173,789 ) (139,927 ) $ 244,822 $ 499,993 Depreciation expense related to property and equipment for the nine months ended April 30, 2020 and 2019 was $146,712 and $150,744, respectively.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Apr. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Note 7 – Goodwill and Intangible Assets Intangible assets consist of the following at: Estimated April 30, July 31, Useful Lives 2020 2019 In-Process Research & Development $ 8,761,427 $ 8,761,427 Non-compete agreements 3 years 1,566,700 1,210,000 Developed software/technology 5 years 172,500 131,000 Vendor agreements and other intangibles 775,674 51,274 11,276,301 10,153,701 Less accumulated amortization (781,727 ) (319,432 ) $ 10,494,574 $ 9,834,269 Intangible assets are generally amortized on a straight-line basis over the useful lives of the assets. The Company is currently not amortizing the in-process research and development until it becomes commercially viable and placed in service. At the time when the intangible assets are placed in service the Company will determine a useful life. As of April 30, 2020, the in-process research and development (“IPR&D”) of $8,761,427 in the aggregate was a combination of $2,911,377 obtained through the acquisition of HDS; $3,391,050 obtained through the acquisition of Regentys; and $2,459,000 through the acquisition of Olaregen. None of the research and development underlying the IPR&D has been not been abandoned, nor was it determined to be impaired by management as a result of COVID-19. The Company was recently awarded a Blanket Purchase Agreement (BPA) contract from the National Strategic Acquisition Center (SAC). The VA’s National Contract and National BPA programs are used by VA medical centers, related facilities, specific State Veterans Homes, and other Federal facilities to procure select products based on clinical evidence, patient outcomes, and economic cost to the VA hospitals. The SAC awarded Olaregen’s Excellagen will expedite the purchasing of Excellagen at over 165 VA medical centers across the U.S. and Puerto Rico. This approval process is critical to the Company’s ability to determine whether IPR&D associated with Olaregen no longer has an indefinite life subject to amortization, except until the VA resumes its surgical procedures, the Company determined Olaregen’s IPR&D life to remain indefinite as of April 30, 2020. Amortization expense amounted to $462,295 and $399,541 for the nine months ended April 30, 2020 and 2019, respectively. The estimated amortization expense remainder of the current fiscal year and for the next five years and thereafter is as follows: Year Ending July 31, Amount For the period May 1, 2020 to July 31, 2020 $ 154,565 2021 616,744 2022 347,399 2023 94,510 2024 75,018 Thereafter 444,911 Total $ 1,733,147 Changes in the value of goodwill: Balance as of July 31, 2019 $ 38,297,573 Acquisition of MediSource and Pantheon 603,553 Balance as of April 30, 2020 $ 38,901,126

Notes Payable

Notes Payable	9 Months Ended
	Apr. 30, 2020
Debt Disclosure [Abstract]
Notes Payable	Note 8 – Notes Payable On October 26, 2018, Generex entered into a Securities Purchase Agreement with an investor pursuant to which the Company sold its Note Due October 26, 2019 (“Note”) in the principal amount of $682,000 . On January 24, 2019, Generex entered into a Securities Purchase Agreement with an investor pursuant to which the Company sold its convertible note bearing interest at 10% per annum (the “Notes”) in the principal amount of $530,000. The purchase price of the Notes was $505,000 and the remaining $25,000 of principal amount represents original issue discount. Pursuant to the Securities Purchase Agreement, Generex also sold warrants to the investors to purchase 42,399 shares of common stock with the fair value of the warrants as of the date of issuance in excess of the Notes resulting in full discount of the Notes. In February 2019, Generex entered into Securities Purchase Agreements with two investors pursuant to which the Company sold each investor a $750,000 convertible note bearing interest at 10% per annum (the “Notes”). The total purchase price of the Notes was $1,425,000 and the remaining $75,000 of principal amount represents original issue discount. Subject to certain ownership limitations, the Notes will be convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price determined as follows: the lesser of a price determined as of the date of closing; and 70% of the lowest trading price of the common stock on the ten days prior to conversion. The embedded conversion feature of these Notes was deemed to require bifurcation and liability classification, at fair value. Pursuant to the Securities Purchase Agreements, Generex also sold warrants to the investors to purchase up to an aggregate 143,000 shares of common stock. The fair value of the derivative liability and warrants as of the date of issuance was in excess of the Notes (Note 14) resulting in full discount of the Notes. One of the notes went into default during the quarter. Pursuant to a settlement agreement, the Company agreed to settle the debt by making a $900,000 payment and converting $350,000 of the remaining principal into common stock of the Company. The Company recognized a loss on settlement of debt of $403,214. In April 2019, Generex entered into Securities Purchase Agreements with two investors pursuant to which the Company sold convertible notes bearing interest at 10% per annum (the “Notes”) in the aggregate principal amount of $1,060,000. The purchase price of the Notes was $1,000,000 and the remaining $60,000 of principal amount represents original issue discount. Subject to certain ownership limitations, the Notes will be convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price determined as follows: the lesser of a price determined as of the date of closing; and 70% of the lowest trading price of the common stock on the ten days prior to conversion. The embedded conversion feature of these Notes was deemed to require bifurcation and liability classification, at fair value. Pursuant to the Securities Purchase Agreements, Generex also sold warrants to the investors to purchase up to an aggregate 247,755 shares of common stock. The fair value of the derivative liability and warrants as of the date of issuance was in excess of the Notes resulting in full discount of the Notes. In May 2019, the Company consummated a Stock Purchase Agreement entered into January 14, 2019 to which the Company sold $2,000,000 of promissory notes bearing interest at 7% per annum (the “Notes”) originally due and payable on August 1, 2019. The notes remains active and interest has continued to accrue while new terms of the note are in process of being negotiated. In July 2019, Generex entered into Securities Purchase Agreements with two investors pursuant to which the Company sold convertible notes bearing interest at 9% per annum (the “Notes”) in the aggregate principal amount of $446,600. The purchase price of the Notes was $400,000 and the remaining $46,600 of principal amount represents original issue discount. Subject to certain ownership limitations, the Notes will be convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price determined as follows: the lesser of a price determined as of the date of closing; and 80% of the lowest volume weighted average trading price of the common stock on the ten days prior to conversion. The embedded conversion feature of these Notes was deemed to require bifurcation and liability classification, at fair value. The fair value of the derivative liability as of the date of issuance was $206,548 and was recorded as a discount of the Notes. In August 2019, the Company borrowed $1,000,000 from an investor, bearing 10% interest per annum, with an original issue discount of $150,000. $1,150,000 is due in one year from the date of issuance. In August and September 2019, the Company entered into Securities Purchase Agreements with three investors pursuant to which the Company sold convertible notes bearing interest between 9% and 10% per annum (the “Notes”) in the aggregate principal amount of $2,222,500. The purchase price of the Notes was $1,976,745 and the remaining $245,755 of principal amount represents original issue discount. Subject to certain ownership limitations, the Notes will be convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price determined as follows: 80% of the lowest trading price of the common stock on the ten or twenty days prior to conversion. The embedded conversion feature of these Notes was deemed to require bifurcation and liability classification, at fair value. The fair value of the derivative liability as of the date of issuance was $1,052,349 and was recorded as a discount of the Notes. In December 2019, the Company entered into Securities Purchase Agreements with an investor pursuant to which the Company sold a convertible note bearing interest of 12% per annum in the principal amount of $2,200,000. The purchase price of the note was $2,000,000 and the remaining $200,000 of principal amount represents original issue discount. Subject to certain ownership limitations, the note will be convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price of 95% of the lowest stock five trading days prior to conversion less. During the quarter, the Company defaulted on the note for not filing the S-1 within a required period. Thereafter the interest increased to 22% per annum and the conversion price decreased to 85% of the lowest stock five trading days prior to conversion. This embedded conversion feature was deemed to require bifurcation and liability classification, at fair value. The fair value of the derivative liability as of the date of issuance was $111,508 and was recorded as a discount of the note. The investor has subsequently filed suit and the Company is evaluating the claim and has had a preliminary settlement discussion with the plaintiff. During the second quarter of fiscal 2020, the Company entered into Securities Purchase Agreements with four investors pursuant to which the Company sold convertible notes bearing interest between 4% and 10% per annum (the “Notes”) in the aggregate principal amount of $495,000. The purchase price of the Notes was $550,000 and the remaining $55,000 of principal amount represents original issue discount. Subject to certain ownership limitations, the Notes will be convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price. The embedded conversion feature of these Notes was deemed to require bifurcation and liability classification, at fair value. The fair value of the derivative liability as of the date of issuance was $410,828 and was recorded as a discount of the Notes. On February 10, 2020, the Company entered into a Securities Purchase Agreement with an investor pursuant to which the Company sold a convertible note bearing interest at 12% per year in the principal amount of $305,000. The purchase price of the note was $270,000 and the remaining $35,000 of principal amount represents $30,000 of original issue discount and $5,000 of closing costs. Subject to certain ownership limitations, the note will be convertible at the option of the holder at any time into shares of our common stock at an effective conversion price equal to 80% of the lowest closing price as of the date of the notice. Additionally, the Company issued 35,000 shares of common stock to the investor upon execution of the note. On February 19, 2020, a lender made a formal demand for repayment of a note payable due on August 29, 2020 because they claim Company failed to comply with all terms of the note. On April 8, 2020, the Company signed a forbearance agreement with the lender to remove the major default penalty, but increase the annual interest rate to 22%. The balance of the note was amended to $956,535 in cash which includes principal in the amount of $772,500 and approximately $184,035 of accrued interest and penalties. As of April 30, 2020, there were three notes in default with an aggregate principal balance of 3,748,744. The notes are accruing at default rates of interest between 22% and 24% per annum. On February 28, 2020, the Company entered into a series of Securities Purchase Agreements with three investors pursuant to which the Company agreed to sell and sold convertible notes bearing interest at 9.5% per year in the aggregate principal amount of $281,600. The purchase price of the notes in the aggregate was $250,000 and the remaining $31,600 of principal amount represents original issue discount. Subject to certain ownership limitations, the notes will be convertible at the option of the holder at any time into shares of our common stock at an effective conversion price equal 80% of the lowest closing price for the ten trading days prior to the day of the notice. On April 9, 2020, the Company issued a note to a lender for $50,000 due in year with an interest rate of 10% per annum. The funds were paid directly to one of the Company’s vendors. In April, 2020, Regentys, Olaregen, NDS 2 and MediSource (collectively “the Subsidiaries”) were granted loans (the “PPP Loans”) in the aggregate amount of $499,473, pursuant to the Paycheck Protection Program (the “PPP”) under Division A, Title I of the CARES Act, which was enacted March 27, 2020. The application for these funds required the Company to, in good faith, certify that the current economic uncertainty made the loan request necessary to support the ongoing operations of the Company. This certification further required the Subsidiaries to consider its current business activity and its ability to access other sources of liquidity sufficient to support ongoing operations in a manner that is not significantly detrimental to the business. The receipt of these funds, and the forgiveness of the loan attendant to these funds, is dependent on the Subsidiaries having initially qualified for the loan and qualifying for the forgiveness of such loan based on its future adherence to the forgiveness criteria. The PPP Loans, which were in the form of a notes with dates ranging between April 17 and April 24, 2020 and mature between two and five years and bear interest at a rate of 1.00% per annum, payable in monthly payments commencing six months after loan disbursements. The notes may be prepaid by the Subsidiaries at any time prior to maturity with no prepayment penalties. Funds from the PPP Loan may only be used for payroll costs and any payments of certain covered interest, lease and utility payments. The Company intends to use the entire PPP Loan amount for qualifying expenses. Under the terms of the PPP, certain amounts of the Loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. No assurance can be provided that the Company will obtain forgiveness of the PPP Loan in whole or in part. Amount Balance of notes payable at July 31, 2019 $ 8,368,379 Issuances of debt 5,492,242 Issuance of PPP loans 499,473 Increase in debt due to default 92,619 Debt discount (971,563 ) Amortization of debt discount 3,795,605 Conversions (4,275,760 ) Payments (935,731 ) Balance of notes payable at April 30, 2020 $ 12,065,264 On December 28, 2017, the Company through its then wholly owned subsidiary NuGenerex Distribution Solutions, LLC (“NuGenerex”), completed the acquisition of the assets and 100% of the membership interests of two pre-operational pharmacies, Empire State Pharmacy Holdings, LLC and Grainland Pharmacy Holdings, LLC, pursuant to the bills of sale for a consideration of $320,000 Promissory Note due and payable in full on June 28, 2018 bearing an annual interest rate of 3%. The note was extended by six months and set to mature with the same terms on December 28, 2018. The note remains active and interest has continued to accrue while new terms of the note are in process of being negotiated. Pursuant to the second closing of the acquisition of certain operating assets of Veneto Holdings, L.L.C. and its affiliates, Generex’s wholly owned subsidiary agreed to assume outstanding debt of Veneto subsidiaries to Compass Bank, including obligations under a term loan and a revolving line of credit. Claiming three separate types of default, Compass Bank has demanded payment in full of amounts due under the term loan and revolving line of credit, in an aggregate amount of approximately $3,413,000. Generex believes it has defenses to such demand, including that the bank was not an intended beneficiary of the subsidiary’s agreement to assume the debt. Pursuant to its acquisition of Regentys, the Company inherited convertible notes with several investors which collectively held a principal plus of $615,000 as of the date of acquisition. As of April 30, 2020, the remaining principal balance was $353,375 with an unamortized debt discount balance of $16,824. These notes have an accrued interest balance of $67,383 as of April 30, 2020.

Derivative Liability

Derivative Liability	9 Months Ended
	Apr. 30, 2020
Notes to Financial Statements
Derivative Liability	Note 9 – Derivative Liability The Company issued debts that consist of the issuance of convertible notes with variable conversion provisions. The conversion terms of the convertible notes are variable based on certain factors, such as the future price of the Company’s common stock. The number of shares of common stock to be issued is based on the future price of the Company’s common stock. The number of shares of common stock issuable upon conversion of the promissory note is indeterminate. Due to the fact that the number of shares of common stock issuable could exceed the Company’s authorized share limit, the equity environment is tainted, and all additional convertible debentures and warrants are included in the value of the derivative liabilities. Pursuant to ASC 815-15 Embedded Derivatives, the fair values of the variable conversion options and warrants and shares to be issued were recorded as derivative liabilities on the issuance date and revalued at each reporting period. Based on the various convertible notes described in Note 9, the fair value of applicable derivative liabilities on notes, warrants and change in fair value of derivative liability are as follows as of April 30, 2020: following table presents the activity for derivative liabilities measured at estimated fair value: Derivative Liability - Convertible Notes Derivative Liability - Warrants Derivative Liability - Downside Protection Total Balance as of July 31, 2019 $ 4,156,196 $ 325,250 $ 3,338,836 $ 7,820,282 Additions during the period 1,804,254 30,353 — 1,834,607 Change in fair value (1,045,434 ) (9,913 ) 4,764,341 3,708,994 Change due to conversion / exercise / redemptions (3,007,387 ) (36,435 ) — (3,043,822 ) Balance as of April 30, 2020 $ 1,907,629 $ 309,255 $ 8,103,177 $ 10,320,061

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Apr. 30, 2020
Equity [Abstract]
Stockholders' Equity	Note 10 - Stockholders’ Equity Stock Split and Dividend On November 13, 2018, the Company declared a stock dividend on its outstanding Common Stock for stockholders of record date to be determined (the “Record Date”). As a result, all stockholders on the Record Date received twenty new shares of Common Stock for each share of Common Stock owned by them as of that date. On February 24, 2020, Generex issued a 1.4:1 stock split (the “Stock Split”) and paid a stock dividend (“Stock Dividend”) consisting of two shares of NGIO for every five shares of Generex, or 40%. Some stockholders and option holders waived their rights to participate in the 1.4:1 stock split and the 40% Stock Dividend. Proportional adjustments for the stock split was made to the Company’s outstanding stock options, and warrants including all share and per-share data, for all amounts and periods presented in the condensed interim consolidated financial statements. Common Stock Shares issued for services In January and February of 2020, the Company issued 669,803 shares of common stock to vendors for services valued between $0.44 and $0.46 per share, or $293,600. Shares issued for deferred offering On November 25, 2019 , the Company entered an Equity Purchase Agreement with an investor to purchase up to $40,000,000 of the Company’s stock at 92% of the market price for the period of five (5) consecutive trading days immediately subject to a put notice on such date on which the Purchase Price is calculated in accordance with the terms and conditions of the agreement (subject to certain limitations) from time to time over a 36-month period. The Company also issued 1,719,901 common stock of Commitment Shares upon execution of the agreement as consideration for the investor’s commitment to purchase additional shares of our common stock pursuant to the agreement. (Note 12) Issuance of common stock payable During the nine months ended April 30, 2020 and 2019, 436,121 and 8,495,924 shares of common stock payable were issued, respectively. As of April 30, 2020 and 2019, 410,928 and 400,928 shares remain to be issued resulting in common stock payable $186,972 and 201,294, respectively. Conversion of debt to equity During the nine months ended April 30, 2020, the Company issued 9,719,740 shares of common stock for the conversion of $4,489,910 of debt. Issuance of common stock for acquisitions In August 2019, the Company issued 400,000 and 560,000 shares of common stock valued at $2.50 per share for the acquisition of MediSource and Pantheon, respectively. Cancellation of shares On September 12, 2019, 20,375,900 outstanding shares of common stock were cancelled by the Company held by Joe Moscato TTEE Friends of Generex Biotechnology Investment Trust U/A/D 4/2/2019, a trust formed for the benefit the Company and any 80% controlled subsidiary of the Company by several shareholders contributing in the aggregate 33,175,900 shares of the Company’s Common Stock and 8,293,975 shares of NGIO commons shares (the “Friends of Generex Trust”), similar to the Stock Control Agreement previously entered into by the same shareholders on December 1, 2018 filed in an 8-K filed on December 3, 2019, incorporated herein by reference. Purchase of shares in subsidiary On August 16, 2019, the Company entered into a Share Exchange Agreement to purchase an additional 900,000 shares of common stock in Olaregen from other shareholders of Olaregen in exchange for 1,905,912 shares of Generex common stock and 476,478 shares of NGIO common stock which increased our interest in Olaregen to approximately 77% of the Olaregen’s outstanding voting shares. On February 14, 2020, the remaining shareholders of Olaregen exchanged all of its outstanding shares for 5,950,000 shares of Generex common stock and 2,765,000 shares of NGIO. In total, during the nine months ended April 30, 2020, the Company issued 7,855,912 shares of stock for the purchase of the outstanding shares in Olaregen, Shares issued as debt issuance cost During the nine months ended April 30, 2020, the Company issued 343,000 shares of common stock to investors as debt issuance cost in conjunction with the issuance of notes payable which were valued at priced per share between $0.26 and $0.51, or total of $151,230. Settlement of subsidiary's liability with stock On February 14, 2020, the former stockholders of Olaregen settled a $32,212 payroll related liability using previously issued Generex common stock it had received from its share exchange. Series H and Series I Convertible Preferred Stock The Company has authorized 109,000 shares of designated non-voting Series H Convertible Preferred Stock with a stated value of $1,000 per share and authorized 6,000 shares of designated non-voting Series I Convertible Preferred Stock with a stated value of $47.61 per share pursuant to the Purchase Agreement dated March 27, 2017. The Series H Preferred Stock was scheduled to be sold in four tranches to the Purchaser. The Series H and Series I Convertible Preferred Stock were convertible at the option of the holder. At closing of the first tranche on March 28, 2017, the Company issued 63,000 shares of Series H Preferred Stock for a purchase price of $3,000,000. On December 1, 2018, after payment of the dividend, B-H Sanford, LLC, converted all of its holding of the Company’ Series H Convertible Preferred Stock owned by it into 28,828,953 shares of common stock. On November 30, 2018, Joseph Moscato, the Company’s President and Chief Executive Officer, and Lawrence Salvo, a member of the Company’s Board of Directors, converted all shares of the Company’ Series I Convertible Preferred Stock owned by them receiving the aggregate 7,595,350 shares. Non-controlling Interest Regentys Pursuant to the Company’s acquisition of Regentys on January 7, 2019 to acquire a 51% interest, the Company was issued 12,048,161 shares of Regentys common stock. As of January 31, 2020, Regentys had a total of 18,623,278 shares of common stock and 2,793,192 Series A voting preferred stock for a total of 21,416,470 total voting shares outstanding. As such, there are 9,368,309 of shares that belong to non-controlling interest shareholders which represents a 43.74% non-controlling interest. Olaregen Pursuant to the Company’s acquisition of Olaregen on January 7, 2019 to acquire a 51% interest, the Company was issued 3,282,632 shares of Olaregen common stock from Olaregen shareholders. In May 2019, the Company issued 4,000,000 shares of common stock contributed and provided by the Friends of Generex Trust and a $2 million note payable for the acquisition of 592,683 shares of Series A Preferred Stock of Olaregen pursuant to a Stock Purchase Agreement entered into January 14, 2019 subject to the approval of the Board of Directors of Olaregen and consummated on May 10, 2019. The provided shares by the Friends of Generex Trust were already issued and outstanding and did not result in any expense of the Company. Since these shares were transferred, to the shareholders of Olaregen, by an existing shareholder to settle an obligation of the Company, the value of the shares provided by the Friends of the Generex Trust to settle the debt was reflected in the financial statements as an addition to contributed (paid-in) capital. After completion Share Exchange Agreement on August 16, 2019, the Company owned 51% of Olaregen. On February 14, 2020, the remaining stockholders of Olaregen exchanged all of its outstanding shares for 5,950,000 shares of Generex common stock and 2,765,000 shares of NGIO. After this transaction and as of April 30, 2020, Generex owns 100% of the outstanding shares of Olaregen. Veneto On November 1, 2018, the Company completed its second closing of Veneto Holdings, L.L.C. (“Veneto”) which granted the Company Rapport Services, LLC (“Rapport”) through the ownership of the units of Class B membership interests providing control of Rapport as only the Class B Member is entitled to elect the nominees to the Board of Managers, which constitute a one percent (1%) ownership in Rapport. The remaining interests represent a 99% non-controlling interest. NuGenerex Immuno-Oncology, Inc. On February 25, 2019, we issued a stock dividend to our shareholders, whereby our shareholders received one (1) share of NGIO for every four (4) shares of our stock held on the dividend date. On March 10, 2020, the Company increased the number of authorized shares from 400,000,000 to 760,000,000, which consists of 750,000,000 shares of common stock, par value $0.001 per share and 10,000,000 shares of preferred stock, par value $0.001 per share. The preferred stock may be issued in one of more series and may have preferences as to dividends and to liquidation of the Company. As of April 30, 2020, 400,000,000 shares of NGIO are issued and outstanding of which 38,357,038 shares belong to non-controlling interest shareholders which represents a 9.59% non-controlling interest.

Redeemable Non-Controlling Inte

Redeemable Non-Controlling Interest	9 Months Ended
	Apr. 30, 2020
Notes to Financial Statements
Redeemable Non-Controlling Interest	Note 11 – Redeemable Non-Controlling Interest Pursuant to the Company’s acquisition of 51% of the outstanding capital stock of Regentys, Regentys had authorized 7,500,000 shares of redeemable Series A Convertible Preferred Stock (“Preferred Stock A”), with a par value of $0.0001 and redemption value of $0.65 per share of which 2,793,192 Preferred Stock A was outstanding as of the date of acquisition and as of January 31, 2020. Preferred Stock may be converted into common stock at the initial conversion ratio of 1:1 which ratio shall be adjusted in accordance with stock dividends, splits, combinations and other similar events, including the sale of additional shares of common or preferred stock and the holders of Preferred Stock A are entitled to vote, together with the holders of Regentys common stock, on all matters submitted to stockholders of Regentys for a vote. At any time after November 1, 2026, the holders of the Company’s Series A Preferred Stock will have the right to require the Company to redeem all or a portion of their shares for cash at a redemption price equal to its liquidation value. Accordingly, this Preferred Stock A was valued to be $4,073,898 at the time of acquisition of Regentys and reclassified as Redeemable Non-Controlling Interest outside of stockholders’ deficit on the consolidated balance sheets.

Subscription Receivable

Subscription Receivable	9 Months Ended
	Apr. 30, 2020
Subscription Receivable
Subscription Receivable	Note 12 – Subscription Receivable On November 25, 2019, the Company entered an Equity Purchase Agreement with an investor to purchase up to $40,000,000 of the Company’s stock at 92% of the market price for the period of five (5) consecutive trading days immediately subject to a put notice on such date on which the purchase price is calculated in accordance with the terms and conditions of the agreement (subject to limitations) from time to time over a 36-month period. The Company issued 1,719,901 shares of common stock (“Commitment Shares”) to the investor upon execution of the agreement as consideration for the investor’s commitment to purchase additional shares of our common stock pursuant to the agreement. The investor will be required to return half of such shares to the Company if the Company determines, in its discretion, to terminate the agreement within 6 months of a registration statement including this agreement as being declared effective pursuant to a registration rights agreement with the investor which the Company filed with the SEC the registration on February 2, 2018. As of the date this quarterly report was filed, the registration statement has not been declared effective. There shares were valued at $0.45 per share, or $767,690 and have been recorded as a subscription receivable until such time that funding has occurred, or pursuant to the completion of other conditions of the agreement.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Apr. 30, 2020
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Note 13 - Stock-Based Compensation Stock Option Plans The Company has two stockholder-approved stock incentive plans under which shares and options exercisable for shares of common stock have been or may be granted to employees, directors, consultants and advisors. A total of 2,835,000 shares of common stock are reserved for issuance under the 2006 Stock Plan as amended (the 2006 Plan) and 240,000,000 shares of common stock reserved for issuance under the 2017 Stock Option Plan (the 2017 Plan). At April 30, 2020, there were 2,818,830 and 230,892,975 shares available under the 2006 Plan and 2017 Plan, respectively. The Company issues new shares of common stock from the shares reserved under the respective Plans upon conversion or exercise of options and issuance of restricted shares. The 2006 and 2017 Plans (the Plans) are administered by the Board of Directors (the Board). The Board is authorized to select from among eligible employees, directors, advisors and consultants those individuals to whom options are to be granted and to determine the number of shares to be subject to, and the terms and conditions of the options. The Board is also authorized to prescribe, amend and rescind terms relating to options granted under the Plans. Generally, the interpretation and construction of any provision of the Plans or any options granted hereunder is within the discretion of the Board. The Plans provide that options may or may not be Incentive Stock Options (ISOs) within the meaning of Section 422 of the Internal Revenue Code. Only employees of the Company are eligible to receive ISOs, while employees and non-employee directors, advisors and consultants are eligible to receive options which are not ISOs, i.e. “Non-Qualified Options.” The options granted by the Board in connection with its adoption of the Plans were Non-Qualified Options. In addition, the 2006 Plan also provides for restricted stock grants. The fair value of each option granted is estimated on the grant date using the Black-Scholes option pricing model or the value of the services provided, whichever is more readily determinable. The Black-Scholes option pricing model takes into account, as of the grant date, the exercise price and expected life of the option, the current price of the underlying stock and its expected volatility, expected dividends on the stock and the risk-free interest rate for the term of the option. The following is a summary of the common stock options granted, forfeited or expired and exercised under the Plan: Options Weighted Average Exercise Price per Share Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Outstanding - July 31, 2019 8,116,495 $ 0.84 7.21 $ 15,961,391 Granted 1,404,200 $ 1.49 4.42 — Forfeited or expired (642,500 ) $ 0.79 5.78 — Exercised — — — — Outstanding – April 30, 2020 8,878,195 $ 0.93 6.20 $ 439,979 The intrinsic value is calculated as the difference between the market value and the exercise price of the shares on April 30, 2020. The market value was $0.46 based on the closing bid price for April 30, 2020. There were 5,432,887 vested common stock options under the Plan as of April 30, 2020. The compensation expense was $1,630,111 for the nine months ended April 30, 2020. The Company had $3,593,298 of unrecognized compensation costs related to non-vested share-based compensation arrangements granted under the Plan at April 30, 2020 to be recognized over an average of 2.52 years. The Company estimated the fair value of each stock option on the grant date using a Black-Scholes option-pricing model. Black-Scholes option-pricing models requires the Company to make predictive assumptions regarding future stock price volatility, recipient exercise behavior, and dividend yield. The Company estimated the future stock price volatility using the historical volatility over the expected term of the option. The following assumptions were used in the Black-Scholes option-pricing model: April 30, 2020 Exercise price $1.44 – 1.49 Time to expiration 5 years Risk-free interest rate 1.51% - 1.59 % Estimated volatility 153.4 % Expected dividend — Stock price at valuation date $1.44 – 1.49 During 2019, the Company established a Direct Stock Purchase Plan (“2019 Plan”) pursuant to which eligible participants may acquire shares of common stock in lieu of certain cash obligations otherwise owed to participants during the 2019 calendar year. The 2019 Plan automatically terminated on December 31, 2019. There was a total of 1,680,000 shares of common stock reserved under the plan of which no shares have been issued.

Warrants

Warrants	9 Months Ended
	Apr. 30, 2020
Warrants Abstract
Warrants	Note 14 - Warrants A summary of the Company’s warrant activities is as follows: Number of Warrants Weighted Average Exercise Price per Share Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Outstanding - July 31, 2019 21,559,553 $ 1.81 0.40 $ 4,500,000 Issued 88,000 2.50 2.29 — Forfeited (80,000 ) 2.50 — — Expired (21,000,000 ) 1.79 0.01 — Outstanding – April 30, 2020 567,553 $ 2.50 2.45 $ — During the nine months ended April 30, 2020, the Company issued 88,000 warrants to investors of convertible notes and 21,000,000 warrants expired due to the passage of time, and 80,000 warrants were forfeited upon settlement of a note. All the warrants issued vested immediately upon issuance. Additionally, 84,000 warrants are to be issued to AEXG in connection with an arbitrator’s award.

Net Income Per Share (EPS)

Net Income Per Share (EPS)	9 Months Ended
	Apr. 30, 2020
Accounting Policies [Abstract]
Net Income Per Share (EPS)	Note 15 - Net Income Per Share (“EPS”): Basic net income or loss per share is calculated using the weighted average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing income available to common shareholders by the weighted average number of common shares outstanding for the period and, when dilutive, potential shares from stock options and warrants to purchase common stock, using the treasury stock method. Common stock equivalents are included in the diluted income per share calculation only when option exercise prices are lower than the average market price of the common shares for the period presented. Three Months Ended April 30, Nine Months Ended April 30, 2020 2019 2020 2019 Weighted average number of common shares outstanding - Basic 76,976,925 84,507,030 70,702,570 74,445,373 Potentially dilutive common stock equivalents — — — — Weighted average number of common and equivalent shares outstanding - Diluted 76,976,925 84,507,030 70,702,570 74,445,373 The following table provides weighted average number of common stock equivalents not included in diluted income per share, because the effects are anti-dilutive, as of April 30, 2020 and 2019, respectively. Nine Months Ended April 30, 2020 2019 Convertible debt 12,923,232 8,339,288 Stock options 9,123,195 6,228,095 Warrants 567,553 559,553 Total 22,613,980 15,126,936

Acquisitions

Acquisitions	9 Months Ended
	Apr. 30, 2020
Business Combinations [Abstract]
Acquisitions	Note 16 – Acquisitions: MediSource and Pantheon: On August 1, 2019, the Company, through its wholly owned subsidiary NDS, closed on Asset Purchase Agreements (the “APAs”) for the purchase of substantially all the operating assets of MediSource Partners, LLC (“MediSource”) and Pantheon Medical - Foot & Ankle, LLC (“Pantheon”). MediSource contracts with vendors (including Pantheon) for nationwide distribution of implants and devices for spine, hips, knees, foot, ankle, hand, and wrist surgeries. Additional product lines include biologics (blood, bone, tissue, and stem cells), durable medical equipment, and soft goods. MediSource also supplies kits to process bone marrow aspirates and platelet rich plasma biologics at the time of surgery. Pantheon sells a physician friendly, “all-in-one,” integrated kit that includes plates, screws, and tools required for orthopedic surgeons and podiatrists conducting foot and ankle surgeries. Over the next three years, Pantheon expects to develop and submit several new product lines to the FDA, which will include cannulated surgical screws and surgical staples, as well as a proprietary Hammertoe System. The goal in acquiring these operating companies is that they expect to provide multiple and significant revenue streams through delivery of patient-focused healthcare products and services, thus generating value and ultimately creating goodwill upon acquisition. Travis H. Bird was the CEO and principal owner of both Pantheon and MediSource. Under the APAs: • Generex issued 400,000 shares of common stock in exchange for the Pantheon assets, and 560,000 shares of common stock in exchange for the MediSource assets. • Generex and NDS will pay up to $700,000 in cash to Pantheon as an earn out payment. No payment will be made unless the business conducted by NDS using the former Pantheon assets has EBITDA in the twelve months following closing in excess of $500,000. If the Pantheon business’s EBITDA meets or exceeds $1,000,000, the entire $700,000 will be paid. If the Pantheon business’s EBITDA exceeds $500,000 but is less than $1,000,000, a pro rata portion of the $700,000 earn-out will be paid. • Generex and NDS will pay up to $500,000 in cash to MediSource as an earn out payment. No payment will be made unless the business conducted by NDS using the former MediSource assets has EBITDA in the twelve months following closing in excess of $130,000. If the MediSource business’s EBITDA meets or exceeds $500,000, the entire $500,000 will be paid. If the MediSource business’s EBITDA exceeds $130,000 but is less than $500,000, a pro rata portion of the $500,000 earn-out will be paid. • In the event the EBITDA targets are met for one or both MediSource and Pantheon, Travis Bird will receive sales commissions equal to 15% of net sales during the first year following closing, and 10% of net sales during the second year. • Both MediSource and Pantheon agreed to waive the 1.4:1 stock split. • Each of Pantheon and MediSource will retain 50% of its cash on hand and 50% of its accounts receivable, with the remainder transferred to NDS at closing. • Generex and NDS will not assume any Pantheon or MediSource liabilities except for post-closing obligations under assumed contracts. • Pantheon and MediSource will not transfer their Medicare and Medicaid numbers. At closing, Mr. Bird entered into an 18-month consulting agreement with NDS. As compensation, Mr. Bird will receive Generex common stock with a value of $250,000, as well as monthly payments equaling $97,222. The monthly payments shall be paid from any available cash from the operations of Pantheon and MediSource. Any remaining balance of such monthly payments will consist of common stock. The agreement specifies the shares are to be freely tradeable. In addition, Mr. Travis will agree to fully assign and exchange any ownership rights in any new technology he develops with the Company, in exchange for a payment of $500,000 in value of common stock for each completed item submitted to the FDA. The Company accounted for the Acquisition of MediSource and Pantheon as a business combination using the purchase method of accounting as prescribed in Accounting Standards Codification 805, Business Combinations (“ASC 805”) and ASC 820 – Fair Value Measurements and Disclosures (“ASC 820”). In accordance with ASC 805 and ASC 820, we used our best estimates and assumptions to accurately assign fair value to the tangible assets acquired, identifiable intangible assets and liabilities assumed as of the acquisition dates. Goodwill as of the acquisition date is measured as the excess of purchase consideration over the fair value of tangible and identifiable intangible assets acquired and liabilities assumed. Fair Value of the MediSource Acquisition The following table summarizes the allocation of the preliminary purchase price as of the MediSource acquisition: Preliminary Cash and cash equivalents $ 13,895 Other current assets 11,864 Property and equipment, net 8,992 Accounts payable and accrued liabilities (31,439 ) Net Tangible Assets $ 3,312 Tradename / Trademarks 47,600 Business Contracts 346,800 Non-Competes 124,600 Total Fair Value of Assets Acquired 522,312 Consideration: Fair value of common stock 479,980 Contingent consideration 409,790 Consideration included in consulting agreement 104,168 Total Purchase Price 993,938 Goodwill $ 471,626 Fair Value of the Pantheon Acquisition The following table summarizes the allocation of the preliminary purchase price as of the Pantheon acquisition: Preliminary Cash and cash equivalents $ 35,410 Accounts receivable 133,269 Prepaid expenses 3,336 Inventory 266,071 Medical Equipment, net 67,299 Accounts payable (53,242 ) Accrued liabilities (15,573 ) Net Tangible Assets $ 436,570 Tradename / Trademarks 55,400 IP/Technology 41,500 Non-compete agreement 232,100 Customer Base 274,600 Total assets acquired $ 1,040,170 Consideration: Fair value of common stock 671,972 Contingent consideration 354,292 Consideration included in consulting agreement 145,833 Goodwill $ 131,927 The components of the acquired intangible assets were as follows: Preliminary Average Estimated Life Tradename / Trademarks $ 103,000 15 IP/Technology 41,500 5 Business Contracts 346,800 15 Customer Base 274,600 10 Non-compete agreement 356,700 3 $ 1,112,600 The components of the purchase consideration as of April 30, 2020 and 2019 is as follows: Balance Sheet Components As of April 30, 2019 As of April 30, 2020 Warrants to be issued — — Call Option — — Pantheon — 473,949 MediSource — 409,763 Total Balance of Contingent Consideration — 883,712 The components in the change in fair value of the purchase consideration for the nine months ending April 30, 2020 and 2019 is as follows: Nine months ending April 30, 2019 Nine months ending April 30, 2020 Warrants to be issued 15,930,072 — Call Option (782,481 ) — Pantheon — 64,159 MediSource — 55,471 Change in fair value of purchase consideration 15,147,591 119,630 Unaudited Supplemental Pro Forma Data Unaudited pro forma results of operations for the three and nine months ended April 30, 2020 and 2019 as though the Company acquired MediSource and Pantheon on the first day of each fiscal year are set forth below. Three Months Ended Nine Months Ended April 30, April 30, 2020 2019 2020 2019 Revenues $ 498,676 $ 1,515,036 $ 2,077,764 $ 7,624,831 Cost of revenues 116,292 1,366,268 415,569 4,570,820 Gross profit 382,384 148,767 1,662,195 3,054,012 Operating expenses 3,956,738 9,387,355 14,343,559 19,607,676 Operating loss (3,574,354 ) 9,238,587 (12,681,364 ) (16,553,664 ) Other income (expense) (2,186,463 ) (1,853,364 ) (9,672,030 ) 11,028,865 Net loss $ (5,760,817 ) $ 7,385,223 $ (22,353,394 ) $ (5,524,800 ) Comprehensive net loss $ (5,609,420 ) $ (9,944,144 ) $ (21,666,893 ) $ (4,546,148 )

Income Taxes

Income Taxes	9 Months Ended
	Apr. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Note 17 – Income Taxes: The Company has incurred losses since inception, which have generated net operating loss (“NOL”) carryforwards. The NOL carryforwards arise from both United States and Canadian sources. Pre-tax gain or (loss) arising from domestic operations (United States) were $(22,329,887) and $(11,006,793) for the nine months ended April 30, 2020 and the year ended July 31, 2019, respectively. Pre-tax (losses) arising from foreign operations (Canada) were $(23,507) and $(326,461) for the nine months ended April 30, 2020 and the year ended July 31, 2019, respectively. As of April 30, 2020, the Company has NOL carryforwards in Generex Biotechnology Corporation of approximately $227.5 million, of which $196.2 million will expire in 2020 through 2038, and $31.3 million will not expire. Generex Pharmaceuticals Inc. has NOL carryforwards of approximately $34.4 million, which expire in 2025 through 2040. NGIO has NOL carryforwards of approximately $36.2 which will expire in 2020 through 2038. Regentys Corporation has NOL carryforwards of approximately $6.3 million, of which $5.0 million will expire in 2033 through 2038 and $1.3 million will not expire. Olaregen Therapeutics, Inc. has NOL carryforwards of $4.0 million which will not expire. Veneto has NOL carryforwards of $9.8 million which will not expire. Some of these loss carryforwards are subject to limitation due to the acquisition of Regentys, Olaregen and NGIO and may be limited in future years due to certain structural ownership changes which have occurred over the last several years related to the Company’s equity and convertible debenture financing transactions. As of April 30, 2020, the Company had no tax benefits which have not been fully allowed for, and no adjustment to its financial position, results of operations or cash flows was required. The Company has deferred tax assets of over $72 million with a full allowance equal to the to the amount of the deferred tax asset. The Company does not expect that unrecognized tax benefits will increase within the next twelve months. During the period ended April 30, 2020, the Company acquired certain assets of MediSource Partners, LLC and Pantheon Medical. The assets are included within Generex Biotechnology Corporation. The Company records interest and penalties related to tax matters within other expense on the accompanying consolidated statement of operations. These amounts are not material to the consolidated financial statements for the years presented. Generally, tax years 2016 to 2019 remain open to examination by the Internal Revenue Agency or other tax jurisdictions to which the Company is subject. The Company’s Canadian tax returns are subject to examination by federal and provincial taxing authorities in Canada. Generally, tax years 2011 to 2019 remain open to examination by the Canada Revenue Agency or other tax jurisdictions to which the Company is subject. On March 27, 2020, the CARES Act was enacted and signed into law in the U.S. in response to the COVID-19 pandemic. One of the provisions of this law is the temporary suspension of the 80% limitation on the utilization of net operating losses generated in taxable years beginning after December 31, 2017 and before January 1, 2021. Additionally, the CARES Act allows The Company to carryback net operating losses generated in taxable years beginning after December 31, 2017 and before January 1, 2021 to the five previous periods if the company has taxable income in the carryback years. Neither of these modifications are expected to apply to the Company due to the sustained history of losses.

Subsequent Events

Subsequent Events	9 Months Ended
	Apr. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	Note 18 - Subsequent Events: The Company has evaluated subsequent events occurring after the balance sheet date through the date the unaudited condensed interim consolidated financial statements were issued. On May 4, 2020, the Company issued a promissory note to a Lender with a purchase price of $100,000 that matures in one year and has a stated interest rate of 10% per annum. Additionally, the Company will issue 20,000 shares of restricted common stock and 20,000 stock options with an exercise price of $0.43 which was due upon execution of the note. On May 26, 2020, the Company entered into a legal services agreement providing for a portion of legal fees payable in $50,000 cash and 120,000 shares of common stock of which $92,120 was accrued as of April 30, 2020. On June 2 Laboratory calls for Pursuant to the Agreement, Generex will pay to CTL a fee for work plan completion of $939,478. On June 15, 2020, filed Form S-1 offering 1,000,000 shares of its Series A Cumulative Redeemable Perpetual Preferred Stock (“Series A Preferred Stock”) and warrants (“Warrants”) to purchase up to an aggregate of 100,000 shares of the Company’s common stock, par value $0.001 (“Common Stock”). For every ten shares of Series A Preferred Stock purchased, we will issue to such purchaser one Warrant to purchase one share of Common Stock. The Warrants will have an initial per share exercise price of $15.00. The warrants will be exercisable immediately and will expire two years from the date of issuance. Dividends on the Series A Preferred Stock offered hereby are cumulative from the first day of the calendar month in which they are issued and will be payable on the fifteenth day of each calendar month, when, as and if declared by our board of directors. Dividends will be payable out of amounts legally available therefor at a rate equal to 13% per annum per $33.00 of stated liquidation preference per share, or $33.00 per share of Series A Preferred Stock per year. As of the time of this filing, this Form S-1 is not effective pending review by the SEC.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Apr. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with accounting principles U.S. GAAP for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments, considered necessary for a fair presentation have been included. The Company’s fiscal year ends on July 31 of each calendar year. Each reference below to a fiscal year refers to the fiscal year ending in the calendar year indicated. Operating results for the three and nine months ended April 30, 2020 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2020. The balance sheet at April 30, 2020 does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Therefore, these condensed financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended July 31, 2019 as filed with the U.S. Securities and Exchange Commission (“SEC”).
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from those estimates.
Business Combinations	Business Combinations Acquisition cost is measured as the aggregate of the fair value at the date of acquisition of the assets given, equity instruments issued, or liabilities incurred or assumed. Acquisition related costs are expensed as incurred (except for those costs arising on the issue of equity instruments which are recognized directly in equity). Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured at fair value on the acquisition date. Goodwill is measured as the excess of the acquisition cost and the amount of any non-controlling interest, over the fair value of the identifiable net assets acquired.
Revenue Recognition	Revenue Recognition It is the Company’s policy that revenues from product sales is recognized in accordance with ASC 606 “Revenue Recognition.” Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that creates enforceable rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer. The amount of revenue recognized is the amount allocated to the satisfied performance obligation. Adoption of ASC 606 has not changed the timing and nature of the Company’s revenue recognition and there has been no material effect on the Company’s financial statements. Revenue from the pharmacy services is recognized when the prescription is dispensed (picked up by the patient or shipped to the patient using common carrier or delivered by the pharmacies own personnel). At the time of dispensing each pharmacy has a contract with the insurance payor (item (i)); the insurance payor has accepted the claim for reimbursement from the pharmacy (item ii) and informed the pharmacy how much will be paid for the prescription (item (iii)); the insurance payor is now legally obligated to make payment on the accepted claim within a given period proscribed by statute (item (iv)); and, the prescription has been taken from the pharmacy inventory, placed into an individually labeled container specific to the patient, and the patient is able to take possession of the prescription (item (v)). Shipment to or pick up by the patient is the first time that all criteria for revenue recognition have been met. Revenue from the laboratory services is recognized upon the completion of accessions (the requested laboratory test has been performed and the report has been issued to the requesting physician). After the test has been performed and reported, the insurance company and/or patient has an obligation to pay for medically necessary laboratory tests (items (i) and (ii)). Unlike the pharmacy services model, laboratory services are provided prior to insurance company approval; as a result, the seller’s price to buyer is not known until payment is provided (items (iii) and (iv). Based on historical collections, the Company estimates the expected revenues associated with similar tests and recognizes the revenue when testing results have been provided (v). Revenue from NGDx is recognized upon payment at the time the product(s) is released (shipment delivered using a common carrier), and the control is transferred which is simultaneous to when payment received and accepted. Revenue from product sales of Olaregen’s Excellagen® is recorded at the net sales price, or “transaction price,” which includes estimates of variable consideration that result from coupons, discounts, chargebacks and distributor fees, processing fees, as well as allowances for returns and government rebates. Revenue from product sales of Pantheon medical surgical kits used in surgical procedures is recorded all revenue is recognized at a point in time, generally when title of the product and control is transferred to the client which occurs upon the completion of surgical procedure when the product utilized and the medical facility provides a final list of products consumed. The Company constrains revenue by considering factors that could otherwise lead to a probable reversal of revenue. Where appropriate, the Company utilizes the expected value method to determine the appropriate amount for estimates of variable consideration based on factors such as the Company’s historical experience, contractual arrangement and specific known market events and trends. Collectability of revenue is reasonably assured based on historical evidence of collectability between the Company and its customers. Revenue from the provision of management services is recognized in accordance with the contractual terms of the relationship (item i); however, the current agreements in place typically specify that a percentage of the gross margin associated with the third-parties’ sales that the Company facilitates is to be remitted (iii), and as such, the revenue is considered earned upon completion of the third parties’ sales of such products (iv). Like pharmacy services described above, revenue is recognized when the prescription is dispensed (picked up by the patient or shipped to the patient using common carrier or delivered by the pharmacies own personnel) (v). Three months ended April 30, Nine months ended April 30, Revenue Source 2020 2019 2020 2019 Product sales $ 497,386 $ 37,300 $ 2,059,662 $ 37,300 Management services 1,290 80,471 18,168 283,319 Pharmacy sales — 1,020,616 — 5,615,153 Laboratory sales — (45,461 ) — 318,567 Total Revenue $ 498,676 $ 1,092,926 $ 2,077,830 $ 6,254,339 Provisions for estimated sales returns and uncollectible accounts are recorded in the period in which the related sales are recognized based on historical and anticipated rates. The Company determines whether it is the principal or agent for its retail pharmacy contract services on a contract by contract basis. In the majority of its contracts, the Company has determined it is the principal due to it: (i) being the primary obligor in the arrangement, (ii) having latitude in changing the product or performing part of the service, (iii) having discretion in supplier selection, (iv) having involvement in the determination of product or service specifications, and (v) having credit risk. The Company’s obligations under its client contracts for which revenues are reported using the gross method are separate and distinct from its obligations to the third-party pharmacies included in its retail pharmacy network contracts. Pursuant to these contracts, the Company is contractually required to pay the third-party pharmacies in its retail pharmacy network for products sold, regardless of whether the Company is paid by its clients. The Company’s responsibilities under its client contracts typically include validating eligibility and coverage levels, communicating the prescription price and the co-payments due to the third-party retail pharmacy, identifying possible adverse drug interactions for the pharmacist to address with the prescriber prior to dispensing, suggesting generic alternatives where clinically appropriate, and approving the prescription for dispensing. Although the Company does not have credit risk with respect to Retail Co-Payments or inventory risk related to retail network claims, management believes that all of the other applicable indicators of gross revenue reporting are present. For contracts under which the Company acts as an agent, revenue is recognized using the net method.
Adoption of New Accounting Standards	Recently Issued Accounting Pronouncements In January 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception. Topic 480, Distinguishing Liabilities from Equity In February 2018, the FASB issued ASU 2018-02, Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement”, which adds disclosure requirements to Topic 820 for the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. This ASU is effective for interim and annual reporting periods beginning after December 15, 2019. The Company is evaluating the effect that ASU 2018-13 will have on consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Apr. 30, 2020
Accounting Policies [Abstract]
Schedule of revenue recognized	Three months ended April 30, Nine months ended April 30, Revenue Source 2020 2019 2020 2019 Product sales $ 497,386 $ 37,300 $ 2,059,662 $ 37,300 Management services 1,290 80,472 18,168 283,319 Pharmacy sales — 1,020,616 — 5,615,153 Laboratory sales — (45,461 ) — 318,567 Total Revenue $ 498,676 $ 1,092,926 $ 2,077,830 $ 6,254,339

Leases (Tables)

Leases (Tables)	9 Months Ended
	Apr. 30, 2020
Leases [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	Maturity of operating lease liabilities for the remainder of the current fiscal year and the following fiscal years: For the period May 1, 2020 to July 31, 2020 $ 30,109 2021 75,675 2022 38,139 2023 9,682 2024 — Thereafter $ — Total undiscounted operating lease payments 153,605 Less: Imputed interest 13,592 Present value of operating lease liabilities $ 140,013

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Apr. 30, 2020
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory consists of the following components: April 30, July 31, 2020 2019 Raw materials $ 278,310 $ 77,782 Finished goods 632,674 285,226 Total Inventory $ 910,984 $ 363,008

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Apr. 30, 2020
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and equipment, net consisted of the following: April 30, July 31, 2020 2019 Computers and technological assets $ 53,314 $ 163,168 Machinery and equipment 329,976 386,929 Furniture and fixtures 18,725 73,227 Leasehold Improvements 16,596 16,596 418,611 639,920 Less accumulated depreciation (173,789 ) (139,927 ) $ 244,822 $ 499,993

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Apr. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets consist of the following at: Estimated April 30, July 31, Useful Lives 2020 2019 In-Process Research & Development $ 8,761,427 $ 8,761,427 Non-compete agreements 3 years 1,566,700 1,210,000 Developed software/technology 5 years 172,500 131,000 Vendor agreements and other intangibles 775,674 51,274 11,276,301 10,153,701 Less accumulated amortization (781,727 ) (319,432 ) $ 10,494,574 $ 9,834,269
Estimated amortization expense	The estimated amortization expense remainder of the current fiscal year and for the next five years and thereafter is as follows: Year Ending July 31, Amount For the period May 1, 2020 to July 31, 2020 $ 154,565 2021 616,744 2022 347,399 2023 94,510 2024 75,018 Thereafter 444,911 Total $ 1,733,147
Changes in value of goodwill	Changes in the value of goodwill: Balance as of July 31, 2019 $ 38,297,573 Acquisition of MediSource and Pantheon 603,553 Balance as of April 30, 2020 $ 38,901,126

Notes Payable (Tables)

Notes Payable (Tables)	9 Months Ended
	Apr. 30, 2020
Debt Disclosure [Abstract]
Schedule of notes payable	No assurance can be provided that the Company will obtain forgiveness of the PPP Loan in whole or in part. Amount Balance of notes payable at July 31, 2019 $ 8,368,379 Issuances of debt 5,492,242 Issuance of PPP loans 499,473 Increase in debt due to default 92,619 Debt discount (971,563 ) Amortization of debt discount 3,795,605 Conversions (4,275,760 ) Payments (935,731 ) Balance of notes payable at April 30, 2020 $ 12,065,264

Derivative Liability (Tables)

Derivative Liability (Tables)	9 Months Ended
	Apr. 30, 2020
Notes to Financial Statements
Schedule of Derivative Liabilities at Fair Value	Following table presents the activity for derivative liabilities measured at estimated fair value: Derivative Liability - Convertible Notes Derivative Liability - Warrants Derivative Liability - Downside Protection Total Balance as of July 31, 2019 $ 4,156,196 $ 325,250 $ 3,338,836 $ 7,820,282 Additions during the period 1,804,254 30,353 — 1,834,607 Change in fair value (1,045,434 ) (9,913 ) 4,764,341 3,708,994 Change due to conversion / exercise / redemptions (3,007,387 ) (36,435 ) — (3,043,822 ) Balance as of April 30, 2020 $ 1,907,629 $ 309,255 $ 8,103,177 $ 10,320,061

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Apr. 30, 2020
Share-based Payment Arrangement [Abstract]
Common stock options granted, forfeited or expired and exercised	The following is a summary of the common stock options granted, forfeited or expired and exercised under the Plan: Options Weighted Average Exercise Price per Share Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Outstanding - July 31, 2019 8,116,495 $ 0.84 7.21 $ 15,961,391 Granted 1,404,200 $ 1.49 4.42 — Forfeited or expired (642,500 ) $ 0.79 5.78 — Exercised — — — — Outstanding – April 30, 2020 8,878,195 $ 0.93 6.20 $ 439,979
Fair value assumptions used in Black-Scholes option-pricing	The following assumptions were used in the Black-Scholes option-pricing model: April 30, 2020 Exercise price $1.44 – 1.49 Time to expiration 5 years Risk-free interest rate 1.51% - 1.59 % Estimated volatility 153.4 % Expected dividend — Stock price at valuation date $1.44 – 1.49

Warrants (Tables)

Warrants (Tables)	9 Months Ended
	Apr. 30, 2020
Warrants Abstract
Schedule of warrant activities	A summary of the Company’s warrant activities is as follows: Number of Warrants Weighted Average Exercise Price per Share Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Outstanding - July 31, 2019 21,559,553 $ 1.81 0.40 $ 4,500,000 Issued 88,000 2.50 2.29 — Forfeited (80,000 ) 2.50 — — Expired (21,000,000 ) 1.79 0.01 — Outstanding – April 30, 2020 567,553 $ 2.50 2.45 $ —

Net Income Per Share (EPS) (Tab

Net Income Per Share (EPS) (Tables)	9 Months Ended
	Apr. 30, 2020
Accounting Policies [Abstract]
Computation of diluted EPS	Common stock equivalents are included in the diluted income per share calculation only when option exercise prices are lower than the average market price of the common shares for the period presented. Three Months Ended April 30, Nine Months Ended April 30, 2020 2019 2020 2019 Weighted average number of common shares outstanding - Basic 76,976,925 84,507,030 70,702,570 74,445,373 Potentially dilutive common stock equivalents — — — — Weighted average number of common and equivalent shares outstanding - Diluted 76,976,925 84,507,030 70,702,570 74,445,373
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following table provides weighted average number of common stock equivalents not included in diluted income per share, because the effects are anti-dilutive, as of April 30, 2020 and 2019, respectively. Nine Months Ended April 30, 2020 2019 Convertible debt 12,923,232 8,339,288 Stock options 9,123,195 6,228,095 Warrants 567,553 559,553 Total 22,613,980 15,126,936

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Apr. 30, 2020
Components of acquired intangible assets	The components of the acquired intangible assets were as follows: Preliminary Average Estimated Life Tradename / Trademarks $ 103,000 15 IP/Technology 41,500 5 Business Contracts 346,800 15 Customer Base 274,600 10 Non-compete agreement 356,700 3 $ 1,112,600
Components of purchase consideration	The components of the purchase consideration as of April 30, 2020 and 2019 is as follows: Balance Sheet Components As of April 30, 2019 As of April 30, 2020 Warrants to be issued — — Call Option — — Pantheon — 473,949 MediSource — 409,763 Total Balance of Contingent Consideration — 883,712
Components in change in fair value of purchase consideration	The components in the change in fair value of the purchase consideration for the nine months ending April 30, 2020 and 2019 is as follows: Nine months ending April 30, 2019 Nine months ending April 30, 2020 Warrants to be issued 15,930,072 — Call Option (782,481 ) — Pantheon — 64,159 MediSource — 55,471 Change in fair value of purchase consideration 15,147,591 119,630
Supplemental Pro Forma	Unaudited pro forma results of operations for the three and nine months ended April 30, 2020 and 2019 as though the Company acquired MediSource and Pantheon on the first day of each fiscal year are set forth below. Three Months Ended Nine Months Ended April 30, April 30, 2020 2019 2020 2019 Revenues $ 498,676 $ 1,515,036 $ 2,077,764 $ 7,624,831 Cost of revenues 116,292 1,366,268 415,569 4,570,820 Gross profit 382,384 148,767 1,662,195 3,054,012 Operating expenses 3,956,738 9,387,355 14,343,559 19,607,676 Operating loss (3,574,354 ) 9,238,587 (12,681,364 ) (16,553,664 ) Other income (expense) (2,186,463 ) (1,853,364 ) (9,672,030 ) 11,028,865 Net loss $ (5,760,817 ) $ 7,385,223 $ (22,353,394 ) $ (5,524,800 ) Comprehensive net loss $ (5,609,420 ) $ (9,944,144 ) $ (21,666,893 ) $ (4,546,148 )
Medisource
Summary of allocation of preliminary purchase price	The following table summarizes the allocation of the preliminary purchase price as of the MediSource acquisition: Preliminary Cash and cash equivalents $ 13,895 Other current assets 11,864 Property and equipment, net 8,992 Accounts payable and accrued liabilities (31,439 ) Net Tangible Assets $ 3,312 Tradename / Trademarks 47,600 Business Contracts 346,800 Non-Competes 124,600 Total Fair Value of Assets Acquired 522,312 Consideration: Fair value of common stock 479,980 Contingent consideration 409,790 Consideration included in consulting agreement 104,168 Total Purchase Price 993,938 Goodwill $ 471,626
Pantheon [Member]
Summary of allocation of preliminary purchase price	The following table summarizes the allocation of the preliminary purchase price as of the Pantheon acquisition: Preliminary Cash and cash equivalents $ 35,410 Accounts receivable 133,269 Prepaid expenses 3,336 Inventory 266,071 Medical Equipment, net 67,299 Accounts payable (53,242 ) Accrued liabilities (15,573 ) Net Tangible Assets $ 436,570 Tradename / Trademarks 55,400 IP/Technology 41,500 Non-compete agreement 232,100 Customer Base 274,600 Total assets acquired $ 1,040,170 Consideration: Fair value of common stock 671,972 Contingent consideration 354,292 Consideration included in consulting agreement 145,833 Goodwill $ 131,927

Organization of Business and _2

Organization of Business and Going Concern (Details Narrative) - USD ($)	Jan. 07, 2019	Apr. 30, 2020	Jul. 31, 2019	Jan. 18, 2017
Accumulated deficit		$ (440,389,785)	$ (418,727,875)
Working capital deficiency		$ 37,600,000
Secured promissory note Description	On January 7, 2019, the Company closed two separate Acquisition Agreements pursuant to which the Company acquired a 51% interest in both Regentys Corporation (“Regentys”) and Olaregen Therapeutix Inc. (“Olaregen”). Regentys is a regenerative medicine company focused on developing novel treatments for patients with gastrointestinal (GI) disorders. Olaregen is a New York based regenerative medicine company that is preparing to launch its proprietary, patented, wound conforming gel matrix, Excellagen, an FDA 510K cleared wound healing product. In the first quarter of 2020 the Company acquired increased its ownership of Olaregen to 77%.
Hema Diagnostic Systems, LLC
Majority interest				51.00%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2019
Revenue recognised	$ 498,676	$ 1,092,926	$ 2,077,830	$ 6,254,339
Product [Member]
Revenue recognised	497,386	37,300	2,059,662	37,300
Management Services [Member]
Revenue recognised	1,290	80,472	18,168	283,319
Pharmacy Sales [Member]
Revenue recognised	0	1,020,616	0	5,615,153
Laboratory sales [Member]
Revenue recognised	$ 0	$ (45,461)	$ 0	$ 318,567

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details Narrative)	Apr. 30, 2020USD ($)
Accounting Policies [Abstract]
Deferred tax assets	$ 31,876,520

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	Dec. 02, 2019	Dec. 03, 2018	Apr. 30, 2020	Feb. 18, 2020	Nov. 27, 2019	Nov. 25, 2019	Nov. 24, 2019	Nov. 22, 2019	Aug. 22, 2017	Dec. 31, 2011	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2019	Nov. 16, 2012	Mar. 04, 2020	Sep. 30, 2019	Aug. 31, 2019	Jul. 31, 2019	May 31, 2019	Feb. 28, 2019	Jan. 24, 2019	Dec. 02, 2018	Oct. 26, 2018
Commitments and Contingencies									The letter from AEXG counsel claimed that Generex’ acceptance of $3,000,000 in financing from Pharma Trials, LLC, in March 2017, violated the provisions of the MOU prohibiting Generex from seeking other financing, with certain exceptions, for a period of 60 days after execution of the MOU. AEXG has demanded at least $210,000 in cash and 84,000 warrants for Generex stock convertible at $2.50 per share, for attorney’s fees and costs.
Litigation awards for damages		$ 315,695
Litigation awards, exercisable shares																							84,000
Exercise price																							$ 2.50
Note amount			$ 3,748,744								$ 3,748,744	$ 1,060,000	$ 3,748,744	$ 1,060,000			$ 2,222,500	$ 1,150,000	$ 446,600	$ 2,000,000	$ 1,500,000	$ 530,000		$ 682,000
Accrued Liquidated damages			285,613								285,613		285,613
Accrued claim			2,752,235								2,752,235		2,752,235
Attorney's fees													210,000
Legal fees													93,304
Legal cost													12,393
Research and development											332,029	472,010	1,270,600	1,463,015
Breakup fee													2,000,000
Payable to foundation for services			1,315,817								1,315,817		1,315,817						1,315,817
Interest payable to foundation			3,682,812								3,682,812		3,682,812						$ 3,055,945
Interest accrued payable to foundation											218,360	$ 182,629	626,867	$ 524,303
KSKZ Management [Member]
Consulting fees	$ 3,450,000
Damages				$ 2,475,000
ALTuCELL [Member]
Common stock description								ALTuCELL Stock, Generex will issue to ALTuCELL 2,240,000 shares of Generex common stock with an attributed value of $4 million to be issued at the market price of the day at closing, but no less than $0.89 per share. The Company will also pay $2.5 million in cash of which $212,000 has already been paid. In addition to stock and cash at closing, Generex has agreed to pay up to an aggregate of $3,500,000 to ALTuCELL upon ALTuCELL’s attainment of certain milestones.
Advanced to related party			212,000								$ 212,000		$ 212,000
Discover Growth Fund [Member]
Accrued claim																$ 2,200,000
Damages for Unpaid Invoices
Value of damages sought										$ 429,000
Lawsuit filing date										31-Dec-11
Name of Plaintiff										Vendor
Settlement of litigation															$ 125,000
Interest per annum, failure to pay settlement										3.00%
Fixed cost per annum, failure to pay settlement										$ 25,000
Breach of contract and detinue
Counterclaim proceeding										$ 200,000
Olaregen
Intellectual property acquired					$ 650,000
NGIO
Related party cost			1,000,000
Service fees			325,000
NSABP [Member] | Clinical trial agreement [Member]
Research and development			$ 340,000
Alternative Execution Group [Member]
Memorandum of Understanding description		The petition includes a demand of $3,300,360 as the value of the warrants. The arbitrator did not award the specific amount of $3.5 million, but only liquidated damages in the amount of $210,000 and the value of 84,000 warrants “as of today” (the date of the award) plus attorney’s fees, certain costs, prejudgment and post-judgment interest (which continues to run on a daily basis) and arbitration fees.
Olaregen
Stock Purchase Agreement description							Company amended the Stock Purchase Agreement with Olaregen. The Company was obligated to pay in full $11,600,000 to Olaregen by November 30, 2019, in connection with the purchase of Olaregen capital stock. Effective November 24, 2019, the deadline was extended to January 31, 2020.
Regentys
Stock Purchase Agreement description						Company amended the Stock Purchase Agreement with Regentys originally on January 7, 2019. Effective November 25, 2019, the remaining three payments of $2,039,001, $2,000,000, and $3,000,000 are all payable on or before December 30, 2019.

Leases (Details)

Leases (Details)	Apr. 30, 2020USD ($)
Leases [Abstract]
For the period May 1, 2020 to July 31, 2020	$ 30,109
2021	75,675
2022	38,139
2023	9,682
2024	0
Thereafter	0
Total undiscounted operating lease payments	153,605
Less: Imputed interest	13,592
Present value of operating lease liabilities	$ 140,013

Leases (Details Narrative)

Leases (Details Narrative)	9 Months Ended
	Apr. 30, 2020USD ($)
Leases [Abstract]
Operating Lease, Weighted Average Remaining Lease Term	1 year 5 months 20 days
Weighted-average discount rate	9.50%
Operating lease expense	$ 82,715

Inventory (Details)

Inventory (Details) - USD ($)	Apr. 30, 2020	Jul. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 278,310	$ 77,782
Finished goods	632,674	285,226
Total Inventory	$ 910,984	$ 363,008

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	Apr. 30, 2020	Jul. 31, 2019
Property and equipment	$ 418,611	$ 639,920
Less accumulated depreciation	(173,789)	(139,927)
Property and equipment, net	244,822	499,993
Computers and technological assets
Property and equipment	53,314	163,168
Machinery and Equipment [Member]
Property and equipment	329,976	386,929
Furniture and Fixtures [Member]
Property and equipment	18,725	73,227
Leasehold Improvements [Member]
Property and equipment	$ 16,596	$ 16,596

Property and Equipment (Detai_2

Property and Equipment (Details Narrative) - USD ($)	9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 146,712	$ 150,744

Goodwill and Intangible Assets_

Goodwill and Intangible Assets: Intangible assets (Details) - USD ($)	9 Months Ended
	Apr. 30, 2020	Jul. 31, 2019
Intangible assets gross	$ 11,276,301	$ 10,153,701
Less accumulated amortization	(781,727)	(319,432)
Intangible assets net	10,494,574	9,834,269
Noncompete Agreements [Member]
Intangible assets gross	$ 1,566,700	1,210,000
Estimated Useful Lives	3 years
Developed Software/Technology [Member]
Intangible assets gross	$ 172,500	131,000
Estimated Useful Lives	5 years
In Process Research and Development [Member]
Intangible assets gross	$ 8,761,427	8,761,427
Vendor agreements and other intangibles [Member]
Intangible assets gross	$ 775,674	$ 51,274

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets: Estimated amortization expense (Details)	Apr. 30, 2020USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
For the period May 1, 2020 to July 31, 2020	$ 154,565
2021	616,744
2022	347,399
2023	94,510
2024	75,018
Thereafter	444,911
Total	$ 1,733,147

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets: Changes in value of goodwill (Details)	9 Months Ended
	Apr. 30, 2020USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Balance at beginning	$ 38,297,573
Acquisition of MediSource and Pantheon	603,553
Balance at end	$ 38,901,126

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets (Details Narrative) - USD ($)	9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Jul. 31, 2019
Amortization expense	$ 462,295	$ 399,541
Intangible assets gross	11,276,301		$ 10,153,701
In Process Research and Development [Member]
Intangible assets gross	8,761,427		$ 8,761,427
In Process Research and Development [Member] | HDS [Member]
Intangible assets gross	2,911,377
In Process Research and Development [Member] | Regentys
Intangible assets gross	3,391,050
In Process Research and Development [Member] | Olaregen
Intangible assets gross	$ 2,459,000

Notes Payable (Details)

Notes Payable (Details) - USD ($)	9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019
Debt Disclosure [Abstract]
Balance of notes paybale at beginning	$ 8,368,379
Issuances of debt	5,492,242
Issuance of PPP loans	499,473
Increase in debt due to default	92,619
Debt discount	(971,563)
Amortization of debt discount	3,795,606	$ 1,128,613
Conversions	(4,275,760)
Payments	(935,731)
Balance of notes payable at end	$ 12,065,264

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	Feb. 10, 2020	Apr. 30, 2020	Feb. 28, 2020	Feb. 19, 2020	Dec. 31, 2019	Aug. 31, 2019	Jul. 31, 2019	May 31, 2019	Apr. 30, 2019	Feb. 28, 2019	Jan. 24, 2019	Oct. 26, 2018	Feb. 19, 2020	Sep. 30, 2019	Apr. 30, 2020	Apr. 30, 2020	Apr. 30, 2019	Dec. 28, 2017
Note amount		$ 3,748,744				$ 1,150,000	$ 446,600	$ 2,000,000	$ 1,060,000	$ 1,500,000	$ 530,000	$ 682,000		$ 2,222,500	$ 3,748,744	$ 3,748,744	$ 1,060,000
Purchase price of note						1,000,000	400,000		1,000,000	1,425,000	505,000	550,000		1,976,745			1,000,000
Investor fee												15,000
Original issue discount						$ 150,000	$ 46,600		$ 60,000	$ 75,000	$ 25,000	$ 147,000		245,755			$ 60,000
Effective interest												27.50%						3.00%
Interest rate				22.00%		10.00%	9.00%	7.00%	10.00%	10.00%	10.00%
Due date								Aug. 1, 2019				Oct. 26, 2019
Number of warrants sold									247,755	143,000	42,399						247,755
Payment of Promissory Note																$ 320,000
Common stock issued for conversion debt, Shares																9,719,740
Common stock issued for conversion debt, Value				$ 956,535												$ 4,489,910
Derivative liability							$ 206,548							$ 1,052,349
Notes payable		$ 12,065,264					$ 8,368,379								12,065,264	12,065,264
Demand for payment description													The demand for payment in the amount of $1,292,621 in cash includes original principal in the amount of $872,500 and approximately $360,442 in penalties.
Subsidiaries [Member]
Interest rate		100.00%
Proceeds from loan		$ 499,473
Regentys
Note amount		353,375													353,375	353,375
Accrued interest																67,383
Debt discount		16,824													16,824	16,824
Minimum [Member]
Interest rate														9.00%			22.00%
Maximum [Member]
Interest rate														10.00%			24.00%
Principal
Common stock issued for conversion debt, Value				772,500												615,000
Interest
Common stock issued for conversion debt, Value				$ 184,035
Notes Payable
Loss on settlement of debt																403,214
Settlement of debt																900,000
Notes Payable | Principal
Common stock issued for conversion debt, Value																350,000
Securities Purchase Agreements [Member] | Investors
Note amount	$ 305,000	495,000			$ 2,200,000										495,000	495,000
Purchase price of note	270,000	550,000			2,000,000										550,000	550,000
Original issue discount	$ 30,000	55,000			$ 200,000										55,000	55,000
Interest rate					12.00%
Derivative liability		$ 410,828			$ 111,508										$ 410,828	$ 410,828
Securities Purchase Agreements [Member] | Investors | Minimum [Member]
Interest rate															4.00%
Securities Purchase Agreements [Member] | Investors | Maximum [Member]
Interest rate															10.00%
Securities Purchase Agreements [Member] | Investor
Note amount			$ 281,600
Purchase price of note			256,000
Original issue discount			$ 25,600
Interest rate	12.00%		9.50%
Closing costs	$ 5,000

Derivative Liability (Details)

Derivative Liability (Details)	9 Months Ended
	Apr. 30, 2020USD ($)
Derivative liabilities at beginning	$ 7,820,282
Additions during the period	1,834,607
Change in fair value	3,708,994
Change due to conversion / exercise / redemptions	(3,043,822)
Derivative liabilities at end	10,320,061
Derivative Liability Convertible Notes
Derivative liabilities at beginning	4,156,196
Additions during the period	1,804,254
Change in fair value	(1,045,434)
Change due to conversion / exercise / redemptions	(3,007,387)
Derivative liabilities at end	1,907,629
Derivative Liability Warrants
Derivative liabilities at beginning	325,250
Additions during the period	30,353
Change in fair value	(9,913)
Change due to conversion / exercise / redemptions	(36,435)
Derivative liabilities at end	309,255
Derivative Liability Downside Protection
Derivative liabilities at beginning	3,338,836
Additions during the period	0
Change in fair value	4,764,341
Change due to conversion / exercise / redemptions	0
Derivative liabilities at end	$ 8,103,177

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	Sep. 12, 2019	Jan. 07, 2019	Mar. 27, 2020	Feb. 24, 2020	Feb. 19, 2020	Feb. 14, 2020	Nov. 25, 2019	Aug. 31, 2019	Aug. 17, 2019	Feb. 29, 2020	Apr. 30, 2020	Apr. 30, 2020	Apr. 30, 2019	Mar. 10, 2020	Jul. 31, 2019
Stock Split				1.4:1
Stock Issued During Period, Value, Issued for Services											$ 50,000	$ 293,600
Issuance of common stock payable, shares												436,121	8,495,924
Issuance of common stock payable, amount												$ 186,972	$ 201,294
Common stock to be issued												410,928	400,928
Common stock issued for conversion debt, Shares												9,719,740
Common stock issued for conversion debt, Value					$ 956,535							$ 4,489,910
Cancellation of common stock	20,375,900
Shares issued as debt issuance cost, shares												343,000
Shares issued as debt issuance cost, value												$ 151,230
Common stock, shares outstanding											79,936,996	79,936,996			78,608,419
Preferred stock, par value														$ 0.001
Preferred stock, Authorized														10,000,000
Preffered stock description			At closing of the first tranche on March 28, 2017, the Company issued 63,000 shares of Series H Preferred Stock for a purchase price of $3,000,000. On December 1, 2018, after payment of the dividend, B-H Sanford, LLC, converted all of its holding of the Company’ Series H Convertible Preferred Stock owned by it into 28,828,953 shares of common stock. On November 30, 2018, Joseph Moscato, the Company’s President and Chief Executive Officer, and Lawrence Salvo, a member of the Company’s Board of Directors, converted all shares of the Company’ Series I Convertible Preferred Stock owned by them receiving the aggregate 7,595,350.
Common stock, par value (in dollars per share)											$ 0.001	$ 0.001		$ 0.001	$ 0.001
Common stock, shares authorized											750,000,000	750,000,000		750,000,000	750,000,000
Generex
Common stock, shares outstanding									1,905,912
NGIO
Common stock, shares outstanding									476,478
Vendors
Stock Issued During Period, Shares Issued for Services										669,803
Stock Issued During Period, Value, Issued for Services										$ 293,600
Investors | Equity Purchase Agreement [Member]
Common stock purchased							$ 40,000,000
Number of common stock issued							1,719,901
Minimum [Member]
Stock Price											$ 0.26	$ 0.26
Minimum [Member] | Vendors
Stock Price										$ 0.44
Maximum [Member]
Stock Price											$ 0.51	$ 0.51
Maximum [Member] | Vendors
Stock Price										$ 0.46
Series I Preferred Stock [Member]
Preferred stock, par value			$ 1,000
Preferred stock, Authorized			109,000
Series H Preferred Stock [Member]
Preferred stock, par value			$ 47.61
Preferred stock, Authorized			6,000
Medisource
Common stock issued for acquisition								400,000
Stock Price								$ 2.50
Pantheon [Member]
Common stock issued for acquisition								560,000
Stock Price								$ 2.50
Olaregen
Payroll related liability						$ 32,212
LOI Terms		Pursuant to the Company’s acquisition of Olaregen on January 7, 2019 to acquire a 51% interest, the Company was issued 3,282,632 shares of Olaregen common stock from Olaregen shareholders. In May 2019, the Company issued 4,000,000 shares of common stock contributed and provided by the Friends of Generex Trust and a $2 million note payable for the acquisition of 592,683 shares of Series A Preferred Stock of Olaregen pursuant to a Stock Purchase Agreement entered into January 14, 2019 subject to the approval of the Board of Directors of Olaregen and consummated on May 10, 2019. The provided shares by the Friends of Generex Trust were already issued and outstanding and did not result in any expense of the Company. Since these shares were transferred, to the shareholders of Olaregen, by an existing shareholder to settle an obligation of the Company, the value of the shares provided by the Friends of the Generex Trust to settle the debt was reflected in the financial statements as an addition to contributed (paid-in) capital. After completion Share Exchange Agreement on August 16, 2019, the Company owned 51% of Olaregen.
Common stock, shares outstanding						5,950,000					7,855,912	7,855,912
Olaregen | Share Exchange Agreement
Number of shares exchanged									900,000
NGIO
Common stock, shares outstanding						2,765,000					400,000,000	400,000,000
Non-controlling interest											38,357,038	38,357,038
Percentage of non-controlling interest											9.59%	9.59%
Regentys
LOI Terms		Pursuant to the Company’s acquisition of Regentys on January 7, 2019 to acquire a 51% interest, the Company was issued 12,048,161 shares of Regentys common stock. As of January 31, 2020, Regentys had a total of 18,623,278 shares of common stock and 2,793,192 Series A voting preferred stock for a total of 21,416,470 total voting shares outstanding. As such, there are 9,368,309 of shares that belong to non-controlling interest shareholders which represents a 43.74% non-controlling interest.

Redeemable Non-Controlling In_2

Redeemable Non-Controlling Interest (Details Narrative) - USD ($)	Apr. 30, 2020	Jul. 31, 2019
Notes to Financial Statements
Redeemable Non-Controlling Int	$ 4,073,898	$ 4,073,898

Subscription Receivable (Detail

Subscription Receivable (Details Narrative) - Equity Purchase Agreement [Member] - Investors	1 Months Ended
	Nov. 25, 2019USD ($)$ / sharesshares
Common stock purchased	$ 40,000,000
Number of common stock issued | shares	1,719,901
Value of common stock issued	$ 767,690
Share Price | $ / shares	$ 0.45

Stock-Based Compensation - Comm

Stock-Based Compensation - Common stock options granted, forfeited or expired and exercised (Details) - USD ($)	9 Months Ended	12 Months Ended
	Apr. 30, 2020	Jul. 31, 2019
Share-based Payment Arrangement [Abstract]
Options Outstanding, Beginning	8,116,495
Options Granted	1,404,200
Options Forfeited or expired	(642,500)
Options Exercised	0
Options Outstanding, End	8,878,195	8,116,495
Weighted Average Exercise Price per Share, Beginning	$ 0.84
Weighted Average Exercise Price per Share, Granted	1.49
Weighted Average Exercise Price per Share, Forfeited or expired	0.79
Weighted Average Exercise Price per Share, Exercised	0
Weighted Average Exercise Price per Share, End	$ 0.93	$ 0.84
Weighted Average Remaining Life Options Outstanding (Years)	6 years 2 months 12 days	7 years 2 months 16 days
Weighted Average Remaining Life Options Granted	4 years 5 months 1 day
Weighted Average Remaining Life Options Forfeited or expired	5 years 9 months 11 days
Aggregate Intrinsic Value Options, Outstanding Beginning	$ 15,961,391
Aggregate Intrinsic Value Options Granted	0
Aggregate Intrinsic Value Options, Outstanding Ending	$ 439,979	$ 15,961,391

Stock-Based Compensation - Fair

Stock-Based Compensation - Fair value assumptions used in Black-Scholes option-pricing (Details)	9 Months Ended
	Apr. 30, 2020$ / shares
Time to expiration	5 years
Estimated volatility	153.40%
Expected dividend	0.00%
Minimum [Member]
Exercise price	$ 1.44
Risk-free interest rate	1.51%
Stock price at period end date	$ 1.44
Maximum [Member]
Exercise price	$ 1.49
Risk-free interest rate	1.59%
Stock price at period end date	$ 1.49

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($)	9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019
Market value	$ 0.46
Compensation expense	$ 1,630,111	$ 1,530,312
Stock Options
Compensation expense	1,630,111
Unrecognized compensation costs	$ 3,593,298
Unrecognized compensation period	2 years 6 months 7 days
Stock Option Plan 2006
Common stock reserved for future issuance	2,835,000
Common stock reserved for future awards	2,818,830
Options vested	5,432,887
Stock Option Plan 2017
Common stock reserved for future issuance	240,000,000
Common stock reserved for future awards	230,892,975
Stock Option Plan 2019
Common stock reserved for future issuance	1,680,000

Warrants (Details)

Warrants (Details)	9 Months Ended
	Apr. 30, 2020USD ($)$ / sharesshares
Warrants Abstract
Number of Warrants Outstanding at beginning	21,559,553
Number of Warrants issued	88,000
Number of Warrants Forfeited	(80,000)
Number of Warrants Expired	(21,000,000)
Number of Warrants Outstanding at end	567,553
Weighted Average Exercise Price per Share Outstanding at beginning | $ / shares	$ 1.81
Weighted Average Exercise Price per Share issued	2.50
Weighted Average Exercise Price per Share Forfeited | $ / shares	$ 2.50
Weighted Average Exercise Price per Share Expired | $ / shares	1.79
Weighted Average Exercise Price per Share Outstanding at end | $ / shares	$ 2.50
Weighted Average Remaining Life of Warrants Outstanding at beginning (Years)	4 months 24 days
Weighted Average Remaining Life of Warrants issued (Years)	2 years 3 months 15 days
Weighted Average Remaining Life of Warrants Forfeited (Years)	4 days
Weighted Average Remaining Life of Warrants Outstanding at end (Years)	2 years 5 months 12 days
Aggregate Intrinsic Value Warrants Outstanding at beginning | $	$ 4,500,000
Aggregate Intrinsic Value Warrants issued | $	0
Aggregate Intrinsic Value Warrants Forfeited | $	0
Aggregate Intrinsic Value Warrants Outstanding at end | $	$ 0

Warrants (Details Narrative)

Warrants (Details Narrative)	9 Months Ended
	Apr. 30, 2020shares
Number of Warrants issued	88,000
Investors
Number of Warrants issued	88,000
Number of warrants forfeited	80,000
Number of warrants expired	21,000,000
AEXG
Number of Warrants issued	84,000

Net Income Per Share (_EPS_) -

Net Income Per Share (“EPS”) - Computation of diluted EPS (Details) - shares	3 Months Ended		9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2019
Accounting Policies [Abstract]
Weighted average number of common shares outstanding - Basic	76,976,925	84,507,030	70,702,570	74,445,373
Potentially dilutive common stock equivalents	0	0	0	0
Weighted average number of common and equivalent shares outstanding-Diluted	76,976,925	84,507,030	70,702,570	74,445,373

Net Income Per Share (_EPS_) _2

Net Income Per Share (“EPS”) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019
Total	22,613,980	15,126,936
Convertible Debt
Total	12,923,232	8,339,288
Stock options
Total	9,123,195	6,228,095
Warrants
Total	567,553	559,553

Acquisitions - Fair Value of th

Acquisitions - Fair Value of the Medisource Acquisition (Details) - USD ($)	Apr. 30, 2020	Aug. 02, 2019	Jul. 31, 2019	Apr. 30, 2019	Jul. 31, 2018
Cash and cash equivalents	$ 416,643		$ 298,485	$ 1,407,837	$ 1,046,365
Other current assets	623,844		275,731
Property and equipment, net	244,822		499,993
Accounts payable and accrued liabilities	(21,537,332)		(14,684,060)
Consideration:
Contingent consideration	883,712			0
Goodwill	38,901,126		$ 38,297,573
Medisource
Cash and cash equivalents		$ 13,895
Other current assets		11,864
Property and equipment, net		8,992
Accounts payable and accrued liabilities		(31,439)
Net Tangible Assets		3,312
Tradename / Trademarks		47,600
Business Contracts		346,800
Non-Competes		124,600
Total Fair Value of Assets Acquired		522,312
Consideration:
Fair value of common stock		479,980
Contingent consideration	$ 409,763	409,790		$ 0
Consideration included in consulting agreement		104,168
Total Purchase Price		993,938
Goodwill		$ 471,626

Acquisitions - Fair Value of _2

Acquisitions - Fair Value of the Pantheon Acquisition (Details) - USD ($)	Apr. 30, 2020	Aug. 02, 2019	Jul. 31, 2019	Apr. 30, 2019	Jul. 31, 2018
Cash and cash equivalents	$ 416,643		$ 298,485	$ 1,407,837	$ 1,046,365
Inventory	910,984		363,008
Medical Equipment, net	244,822		499,993
Consideration:
Contingent consideration	883,712			0
Goodwill	38,901,126		$ 38,297,573
Pantheon [Member]
Cash and cash equivalents		$ 35,410
Accounts receivable		133,269
Prepaid Expenses		3,336
Inventory		266,071
Medical Equipment, net		67,299
Accounts payable		(53,242)
Accrued liabilities		(15,573)
Net Tangible Assets		436,570
Tradename / Trademarks		55,400
IP/Technology		41,500
Non-compete agreement		232,100
Customer Base		274,600
Total assets acquired		1,040,170
Consideration:
Fair value of common stock		671,972
Contingent consideration	$ 473,949	354,292		$ 0
Consideration included in consulting agreement		145,833
Goodwill		$ 131,927

Acquisitions - Estimated amorti

Acquisitions - Estimated amortization expense (Details) - USD ($)	Aug. 02, 2019	Apr. 30, 2020
Noncompete Agreements [Member]
Average Estimated Life		3 years
Preliminary Fair Value
Total	$ 1,112,600
Preliminary Fair Value | Tradename / Trademarks [Member]
Total	$ 103,000
Average Estimated Life	15 years
Preliminary Fair Value | IP/Technology [Member]
Total	$ 41,500
Average Estimated Life	5 years
Preliminary Fair Value | Business Contracts [Member]
Total	$ 346,800
Average Estimated Life	15 years
Preliminary Fair Value | Customer Base [Member]
Total	$ 274,600
Average Estimated Life	10 years
Preliminary Fair Value | Noncompete Agreements [Member]
Total	$ 356,700
Average Estimated Life	3 years

Acquisitions - Components of p

Acquisitions - Components of purchase consideration (Details) - USD ($)	Apr. 30, 2020	Aug. 02, 2019	Apr. 30, 2019
Contingent consideration	$ 883,712		$ 0
Pantheon [Member]
Contingent consideration	473,949	$ 354,292	0
Medisource
Contingent consideration	409,763	$ 409,790	0
Warrants to be issued
Contingent consideration	0		0
Call Option
Contingent consideration	$ 0		$ 0

Acquisitions - Change in fair v

Acquisitions - Change in fair value of purchase consideration (Details) - USD ($)	9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019
Change in fair value of purchase consideration	$ 119,630	$ 15,147,591
Pantheon [Member]
Change in fair value of purchase consideration	64,159	0
Medisource
Change in fair value of purchase consideration	55,471	0
Warrants to be issued
Change in fair value of purchase consideration	0	15,930,072
Call Option
Change in fair value of purchase consideration	$ 0	$ (782,481)

Acquisitions - Unaudited Supple

Acquisitions - Unaudited Supplemental Pro Forma Data (Details) - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2019
Business Combinations [Abstract]
Revenues	$ 498,676	$ 1,515,036	$ 2,077,764	$ 7,624,831
Cost of revenues	116,292	1,366,268	415,569	4,570,820
Gross profit	382,384	148,767	1,662,195	3,054,012
Operating expenses	3,956,738	9,387,355	14,343,559	19,607,676
Operating loss	(3,574,354)	9,238,587	(12,681,364)	(16,553,664)
Other income (expense)	(2,186,463)	(1,853,364)	(9,672,030)	11,028,865
Net loss	(5,760,817)	7,385,223	(22,353,394)	(5,524,800)
Comprehensive net loss	$ (5,609,420)	$ (9,944,144)	$ (21,666,893)	$ (4,546,148)

Acquisitions (Details Narrative

Acquisitions (Details Narrative)	Aug. 02, 2019
Business Combinations [Abstract]
Business combination description	Under the APAs: • Generex issued 400,000 shares of common stock in exchange for the Pantheon assets, and 560,000 shares of common stock in exchange for the MediSource assets. • Generex and NDS will pay up to $700,000 in cash to Pantheon as an earn out payment. No payment will be made unless the business conducted by NDS using the former Pantheon assets has EBITDA in the twelve months following closing in excess of $500,000. If the Pantheon business’s EBITDA meets or exceeds $1,000,000, the entire $700,000 will be paid. If the Pantheon business’s EBITDA exceeds $500,000 but is less than $1,000,000, a pro rata portion of the $700,000 earn-out will be paid. • Generex and NDS will pay up to $500,000 in cash to MediSource as an earn out payment. No payment will be made unless the business conducted by NDS using the former MediSource assets has EBITDA in the twelve months following closing in excess of $130,000. If the MediSource business’s EBITDA meets or exceeds $500,000, the entire $500,000 will be paid. If the MediSource business’s EBITDA exceeds $130,000 but is less than $500,000, a pro rata portion of the $500,000 earn-out will be paid. • In the event the EBITDA targets are met for one or both MediSource and Pantheon, Travis Bird will receive sales commissions equal to 15% of net sales during the first year following closing, and 10% of net sales during the second year. • Both MediSource and Pantheon agreed to waive the 1.4:1 stock split Generex announced it will issue if Generex is listed on NASDAQ. • Each of Pantheon and MediSource will retain 50% of its cash on hand and 50% of its accounts receivable, with the remainder transferred to NDS at closing. • Generex and NDS will not assume any Pantheon or MediSource liabilities except for post-closing obligations under assumed contracts. • Pantheon and MediSource will not transfer their Medicare and Medicaid numbers.

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	9 Months Ended	12 Months Ended
	Apr. 30, 2020	Jul. 31, 2019
Pre-tax gain or (loss) arising from domestic operations	$ (22,329,887)	$ (11,006,793)
Pre-tax (losses) arising from foreign operations	(23,507)	$ (326,461)
Decrease in deferred tax assets	72,000,000
Generex Pharmaceuticals
NOL carryforwards	227,500,000
Antigen Express
NOL carryforwards	36,200,000
Regentys
NOL carryforwards	6,300,000
Olaregen
NOL carryforwards	$ 4,000,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Jun. 02, 2020	May 04, 2020	Jun. 15, 2020	May 26, 2020	Feb. 19, 2020	Aug. 31, 2019	Jul. 31, 2019	May 31, 2019	Apr. 30, 2019	Feb. 28, 2019	Jan. 24, 2019	Apr. 30, 2020	Mar. 10, 2020	Sep. 30, 2019	Oct. 26, 2018
Purchase price of note						$ 1,000,000	$ 400,000		$ 1,000,000	$ 1,425,000	$ 505,000			$ 1,976,745	$ 550,000
Interest rate					22.00%	10.00%	9.00%	7.00%	10.00%	10.00%	10.00%
Exercise price												$ 1.49
Legal fees payable in cash												$ 93,304
Common stock, par value							$ 0.001					$ 0.001	$ 0.001
Subsequent Event [Member] | Warrants [Member]
Warrants issued			100,000
Common stock, par value			$ 0.001
Warrant exercise price			$ 15
Warrant term			2 years
Subsequent Event [Member] | Series A Preferred Stock [Member]
Preffered stock issued			1,000,000
Dividend rate			13.00%
Liquidation preference per share			$ 33
Subsequent Event [Member] | Legal services agreement [Member]
Legal fees payable in cash				$ 50,000
Number of common stock issued for legal fees, shares				92,120
Number of common stock issued for legal fees, amount				$ 120,000
Subsequent Event [Member] | Agreement [Member] | Cellular Technology Limited [Member]
Service fees	$ 939,478
Subsequent Event [Member] | Lender [Member]
Purchase price of note		$ 100,000
Interest rate		10.00%
Number of restricted common stock issued		20,000
Number of options granted		20,000
Exercise price		$ 0.43